Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)
- Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed at the end of the initial 12-month Phase 1/2 trial (Year 1); the Complete Response (CR) rate improved to 50% for Year 2 from 28% for Year 1 Mean number of surgeries patients needed to control their RRP continued to drop from 4.1 surgeries per year prior to receiving INO-3107 to 1.7 for Year 1 to 0.9 for Year 2 Partial data into the third 12-month period (Year 3 - median follow up 2.8 years following initial treatment) continued the trend of improvement and a reduced number of surgeries PLYMOUTH MEETING, Pa. , Aug. 11, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that peer-reviewed data from a retrospective study investigating the long-term clinical and safety response of patients treated with INO-3107 were published online in The Laryngoscope under the title "DNA Immunotherapy (INO-3107) Results in Long-term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP).
- 08/11/2025
|
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
- Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/05/2025
|
INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025
- PLYMOUTH MEETING, Pa. , Aug. 4, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its second quarter 2025 financial results will be released after the market close on August 12, 2025.
- 08/04/2025
|
INOVIO to Present at Upcoming Scientific Conference
- PLYMOUTH MEETING, Pa. , July 7, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting on the potential of next generation DNA medicine technology in rare disease at the upcoming Orphan Drug Summit in Boston, Massachusetts.
- 07/07/2025
|
INOVIO Announces Pricing of $25 Million Public Offering
- PLYMOUTH MEETING, Pa. , July 3, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock and accompanying Series A warrants to purchase up to 14,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price of $1.75 per share of common stock and Series B warrants to purchase up to 14,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price of $1.75 per share of common stock, at a combined public offering price of $1.75 per share of common stock and accompanying Series A and Series B warrants.
- 07/03/2025
|
INOVIO Announces Proposed Public Offering
- PLYMOUTH MEETING, Pa. , July 2, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying Series A warrants and Series B warrants to purchase shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof), in an underwritten public offering.
- 07/02/2025
|
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
- LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development.
- 07/01/2025
|
Inovio Pharmaceuticals, Inc. (INO) Q1 2025 Earnings Call Transcript
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical Officer Steve Egge - Chief Commercial Officer Peter Kies - CFO Conference Call Participants Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Roger Song - Jefferies Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio First Quarter 2025 Financial Results Conference Call.
- 05/13/2025
|
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
- Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $1.31 per share a year ago.
- 05/13/2025
|
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights
- On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025 Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated completion in 1H25 Clinical and immunological results from Phase 1/2 trial of INO-3107 published in Nature Communications in February 2025 INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with significant clinical benefit as measured by reduced need for surgery Announced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encoded monoclonal antibodies (DMAbs) were well tolerated and exhibited long-lasting in vivo production Preprint manuscript available on ResearchSquare.com PLYMOUTH MEETING, Pa. , May 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2025 and provided an update on recent company developments.
- 05/13/2025
|
Inovio Pharmaceuticals, Inc. (INO) Citizens JMP Life Sciences Conference (Transcript)
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Citizens JMP Life Sciences Conference May 8, 2025 11:30 AM ET Company Participants Jacqui Shea - President and CEO Mike Sumner - Chief Medical Officer Conference Call Participants Roy Buchanan - JMP Roy Buchanan All right. Thank you again, everybody, for joining us here at the Citizens Life Sciences Conference.
- 05/09/2025
|
INOVIO to Present at Upcoming Scientific and Investor Conferences
- PLYMOUTH MEETING, Pa. , April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting at several upcoming conferences, including a fireside chat at the Citizens JMP Life Sciences Conference in New York.
- 04/30/2025
|
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025
- PLYMOUTH MEETING, Pa. , April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter 2025 financial results will be released after the market close on May 13, 2025.
- 04/29/2025
|
Bet on These 5 Top-Ranked Stocks With Rising P/E
- Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc.
- 04/21/2025
|
Inovio (INO) Upgraded to Buy: Here's What You Should Know
- Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 04/09/2025
|
INOVIO to Present at Upcoming Scientific Conferences
- PLYMOUTH MEETING, Pa. , April 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will highlight key data associated with its lead candidate, INO-3107, at several upcoming conferences, including an opportunity to join other leading voices at the inaugural National HPV Conference.
- 04/09/2025
|
Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)
- Inovio (INO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 04/01/2025
|
Inovio Pharmaceuticals, Inc. (INO) Q4 2024 Earnings Call Transcript
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical Officer Steve Egge - Chief Commercial Officer Peter Kies - CFO Conference Call Participants Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Yi Chen - H.C. Wainwright Anish Nikhanj - RBC Liang Cheng - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2024 Financial Results Conference Call.
- 03/18/2025
|
INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
- Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and completed drafting of all non-device BLA modules On track to begin rolling submission of BLA in mid-2025 and to request priority review with goal of completing the submission in the second half of 2025 and receiving acceptance of the submission by end of the year Announced durability data from retrospective study showing that 50% of patients achieved a Complete Response in the second 12-month period (year 2) with 86% of patients showing a reduction in surgery of 50% or greater in year 2; data to be included in BLA submission Announced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encoded monoclonal antibodies (DMAb) targeting COVID-19 were well tolerated and exhibited long-lasting in vivo production DMAb technology has the potential to overcome traditional monoclonal antibody production challenges, such as short half-life and anti-drug immune responses, making it a potentially promising platform for a broad range of diseases DNA Medicine technology has the potential to provide long term production of therapeutic antibodies and deliver a broad spectrum of therapeutic proteins that could be used to treat diseases with missing or defective proteins PLYMOUTH MEETING, Pa. , March 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the fourth quarter and full year ended December 31, 2024 and provided a business update and description of operational highlights during the year.
- 03/18/2025
|
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
- Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint No anti-drug antibodies (ADA): no immune rejection of the DMAbs was detected across ~1,000 blood samples, unlike other gene-based antibody delivery approaches where ADA formation has been a challenge Well-tolerated: most common side effects were mild, temporary injection site reactions such as pain and redness; no serious adverse events (SAEs) related to study drug Effective target binding: expressed DMAbs successfully bound to the SARS-CoV-2 Spike protein receptor-binding domain (RBD), confirming functional activity through week 72 PLYMOUTH MEETING, Pa. , March 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced promising interim results from an ongoing Phase 1 proof-of-concept trial evaluating DMAbs for COVID-19.
- 03/13/2025
|
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025
- PLYMOUTH MEETING, Pa. , March 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that fourth quarter and year-end 2024 financial results will be released after the market close on March 18, 2025.
- 03/12/2025
|
Inovio Pharmaceuticals Inc (INO) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Transcript)
- Inovio Pharmaceuticals Inc (NASDAQ:INO ) Oppenheimer 35th Annual Healthcare Life Sciences Conference February 12, 2025 3:20 PM ET Company Participants Jacqui Shea - CEO and President Conference Call Participants Jay Olson - Oppenheimer Jay Olson And our discussion with Inovio. It's a pleasure to introduce Jacqui Shea, CEO and President.
- 02/12/2025
|
Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher
- Inovio (INO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 02/12/2025
|
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications
- Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by reduced need for surgeries PLYMOUTH MEETING, Pa. , Feb. 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that peer-reviewed data from its Phase 1/2 clinical trial with INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) were published online in Nature Communications under the title DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107.
- 02/12/2025
|
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
- Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107 PLYMOUTH MEETING, Pa. , Feb. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that an abstract describing the immunological activity of INO-3107 will be presented as a poster at the following scientific conference: American Association for Cancer Research – Immuno-Oncology Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy (February 23-26, 2025) Poster entitled: "Loss of Detectable HPV-6 Following Induction of Emergent T cells in Patients with Durable Complete Clinical Response to Treatment for Recurrent Respiratory Papillomatosis using INO-3107" The abstract will be made available on INOVIO's website following the conference.
- 02/10/2025
|
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- PLYMOUTH MEETING, Pa. , Jan. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that Dr. Jacqueline Shea, INOVIO's President and CEO, and Dr. Michael Sumner, Chief Medical Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
- 01/29/2025
|
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
- PLYMOUTH MEETING, Pa. , Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings.
- 01/09/2025
|
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet
- U.S. stocks traded mixed toward the end of trading, with the S&P 500 edging lower on Friday.
- 12/13/2024
|
INOVIO Announces Pricing of $30 Million Public Offering
- PLYMOUTH MEETING, Pa. , Dec. 13, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock and accompanying warrants to purchase 10,000,000 shares of its common stock at an exercise price of $3.76 per share of common stock, at a combined public offering price of $3.00 per share of common stock and accompanying warrant.
- 12/13/2024
|
INOVIO Announces Proposed Public Offering
- PLYMOUTH MEETING, Pa. , Dec. 12, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock, in an underwritten public offering.
- 12/12/2024
|
New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial
- Data from a retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP) involved in a Phase 1/2 trial showed the number of patients who met the criteria for a Complete Response (CR) increased to 50% by the end of year 2 and to 54% in year 3, compared to 28% by the end of the initial 52-week trial 95% of patients in the retrospective trial (RRP-002) maintained or enhanced their original Overall Response Rate (ORR) reported in the Phase 1/2 trial (RRP-001) by the end of year 2; 86% of patients maintained or enhanced ORR into year 3 New durability data will help inform re-dosing strategy focused on long-term elimination or reduction in the need for surgery to treat RRP disease INOVIO plans to present data at future scientific conferences and submit for publication in peer-reviewed journals PLYMOUTH MEETING, Pa. , Dec. 3, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced data from a retrospective trial showing that the number of RRP patients meeting the criteria for a Complete Response increased to 50% by the end of the second year following initial treatment with INO-3107 in a previously reported Phase 1/2 52-week trial where the Complete Response rate was 28%.
- 12/03/2024
|
INOVIO Reports Inducement Grant Under Inducement Plan
- PLYMOUTH MEETING, Pa. , Nov. 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
- 11/29/2024
|
European And US Vaccine Stocks Are Under Pressure - Here's WHy
- Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
- 11/15/2024
|
Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Transcript
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q3 2024 Earnings Call Transcript November 14, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of IR Jacqui Shea - President and CEO Mike Sumner - CMO Steve Egge - CCO Peter Kies - CFO Matthew Morrow - VP of Translational Sciences Conference Call Participants Jay Olson - Oppenheimer Roy Buchanan - Citizens JMP Sudan Loganathan - Stephens Liang Cheng - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode.
- 11/14/2024
|
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma Data showed INO-3107 induced expansion of new clonal T cells that infiltrate airway tissues and correspond with reduction of surgeries for RRP patients observed in Phase 1/2 trial Continued progress on preparing regulatory submissions for INO-3107 All non-device BLA modules on track for completion by end of 2024 BLA submission remains targeted for mid-2025 PLYMOUTH MEETING, Pa. , Nov. 14, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the third quarter of 2024 and provided an update on recent company developments.
- 11/14/2024
|
Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial
- New immunology data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment New clonal T cells in the blood travelled to papilloma and airway tissues and generated an inflammatory and anti-viral response consistent with a reduced need for surgeries for patients with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and HPV-11 Data supporting mechanism of action for INO-3107 to be presented at 36th International Papillomavirus Conference in Edinburgh, UK PLYMOUTH MEETING, Pa. , Nov. 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced new immunology data that supports the clinical activity of its lead product candidate, INO-3107, that was previously observed in a Phase 1/2 trial of RRP patients.
- 11/13/2024
|
INOVIO to Present at Upcoming Scientific Conferences
- PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: 36th International Papillomavirus Conference (Edinburgh, UK; November 12-15) Presentation and poster by Dr. Matthew Morrow, VP of Translational Sciences Abstract Title: Treatment of recurrent respiratory papillomatosis with INO-3107 induces significant enrichment in hallmark interferon alpha, interferon gamma and inflammatory molecular signatures in papilloma tissue of responders Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development Abstract Title: Clinical response to INO-3107 treatment for recurrent respiratory papillomatosis is associated with CD4 and CD8 T-Cell activity and cytotoxicity in patient airways Vaccines Summit (Boston, MA; November 13-15) Keynote presentation by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development Abstract Title: DNA Medicines Vaccine Platform for both Prophylactic and Therapeutic Applications: Case Studies in Ebola and Recurrent Respiratory Papillomatosis Abstracts from these conferences will be made available on INOVIO's website following each presentation.
- 11/06/2024
|
INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024
- PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2024 financial results will be released after the market close on November 14, 2024.
- 11/06/2024
|
INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP
- American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy : New immunology data showed ability of INO-3107 to induce an antigen-specific T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma International Society of Vaccines Conference : Full safety and efficacy data from Phase 1/2 clinical study in patients with Recurrent Respiratory Papillomatosis (RRP) indicated that INO-3107 was well tolerated and immunogenic; 81% of patients in the trial required fewer surgeries post-treatment when compared to baseline PLYMOUTH MEETING, Pa. , Oct. 21, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the presentation of new data at scientific conferences for its lead candidate, INO-3107, for which the company is preparing a Biologics License Application for targeted submission in mid-2025 under the U.S. Food and Drug Administration's Accelerated Approval Pathway Program.
- 10/21/2024
|
Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains?
- Inovio (INO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 10/09/2024
|
INOVIO Reports Inducement Grants Under Inducement Plan
- PLYMOUTH MEETING, Pa. , Oct. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to certain employees under its 2022 Inducement Plan (the "Inducement Plan").
- 10/02/2024
|
INOVIO to Present at Upcoming Scientific Conferences
- PLYMOUTH MEETING, Pa. , Oct. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy Poster by Dr. Matthew Morrow, VP of Translational Sciences at INOVIO Abstract Title: Reduction in Surgical Interventions for the Treatment of Recurrent Respiratory Papillomatosis by INO-3107 is Associated with Enriched Macrophage, Dendritic cell and T cell Signatures in Patient Airways Date and Time: October 19, 2024, 6:00 - 8:15pm ET Location: Boston, MA ISV Congress 2024 Oral presentation and poster by Dr. Michael Sumner, Chief Medical Officer at INOVIOAbstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP) Date and Time: October 22, 2024, 4:20pm KSTLocation: Seoul, Korea Fall Voice Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development at INOVIOAbstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP) Date and Time: October 25 – October 26, 2024 Location: Phoenix, AZ World Vaccine Congress Europe Presentation and panel discussion by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development at INOVIOTrack: Pre-Congress Workshop on Platform TechnologiesDate and Time: October 28, 2024, 10:00am CET Location: Barcelona, Spain Abstracts from these conferences will be made available on INOVIO's website following each presentation.
- 10/01/2024
|
INOVIO to Present at Upcoming Scientific Conference
- PLYMOUTH MEETING, Pa. , Sept. 17, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conference: World Congress of Electroporation Oral Presentation by Trevor Smith, VP of Preclinical R&D at INOVIOAbstract Title: Development of in vivo-launched synthetic DNA-encoded antibodies employing CELLECTRA® electroporation technology Date and Time: September 18, 2024, 3:20pm – 3:35pm CET Location: Rome, Italy The abstract from the conference will be made available on INOVIO's website following the data presentation.
- 09/17/2024
|
Inovio Pharmaceuticals, Inc. (INO) Q2 2024 Earnings Call Transcript
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President & Chief Executive Officer Steve Egge - Chief Commercial Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Yi Chen - H.C. Wainwright Operator Good afternoon ladies and gentlemen and welcome to the Inovio Second Quarter 2024 Financial Results Conference Call.
- 08/09/2024
|
INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- PLYMOUTH MEETING, Pa. , Aug. 8, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2024 and provided an update on recent company developments.
- 08/08/2024
|
INOVIO Reports Inducement Grant Under Inducement Plan
- PLYMOUTH MEETING, Pa. , Aug. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
- 08/01/2024
|
Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107
- Data reviewed complies with standards that would be used to evaluate an EU Marketing Authorization Application PLYMOUTH MEETING, Pa. , July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Medicines Agency's Committee for Advanced Therapies (CAT) has certified the quality and non-clinical data for INO-3107, INOVIO's lead candidate for the treatment of Recurrent Respiratory Papillomatosis (RRP).
- 07/25/2024
|
INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024
- PLYMOUTH MEETING, Pa. , July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that second quarter 2024 financial results will be released after the market close on August 8, 2024.
- 07/25/2024
|
Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
- Inovio (INO) soars 19% as its lead candidate, INO-3107, receives the innovative medicine tag under the U.K.'s Innovative Licensing and Access Pathway to treat recurrent respiratory papillomatosis.
- 07/12/2024
|
Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock?
- Inovio (INO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 07/12/2024
|
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway
- Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respiratory Papillomatosis (RRP) PLYMOUTH MEETING, Pa. , July 11, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its lead DNA medicine candidate, INO-3107, has been designated an innovative medicine as part of the U.K.'s Innovative Licensing and Access Pathway (ILAP).
- 07/11/2024
|
INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer
- Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa. , July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer.
- 07/02/2024
|
INOVIO Reports Inducement Grant Under Inducement Plan
- PLYMOUTH MEETING, Pa. , July 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
- 07/01/2024
|
INOVIO Added to Russell 2000® Index Effective July 1, 2024
- PLYMOUTH MEETING, Pa. , July 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes.
- 07/01/2024
|
INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.
- PLYMOUTH MEETING, Pa. , June 4, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner will participate in a virtual fireside chat hosted by Sudan Loganathan, Ph.D.
- 06/04/2024
|
INOVIO Reports Inducement Grants Under Inducement Plan
- PLYMOUTH MEETING, Pa. , May 31, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
- 05/31/2024
|
Better Buy: Inovio Pharmaceuticals vs. Novavax
- Novavax just signed a lucrative agreement with a biotech giant. Inovio Pharmaceuticals is inching closer to launching its leading candidate.
- 05/22/2024
|
Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 2nd Annual BioConnect Investor Conference (Transcript)
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 2nd Annual BioConnect Investor Conference Call May 20, 2024 12:30 PM ET Company Participants Jacqueline Shea - President & Chief Executive Officer Michael Sumner - Chief Medical Officer Unidentified Analyst Welcome to the H.C.
- 05/20/2024
|
Inovio Pharmaceuticals, Inc. (INO) Presents at 2024 RBC Capital Markets Global Healthcare Conference (Transcript)
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) RBC Capital Markets Global Healthcare Conference May 15, 2024 10:00 AM ET Company Participants Jacqueline Shea - CEO Mike Sumner - Chief Medical Officer Conference Call Participants Gregory Renza - Biotechnology Equity Research Analyst, RBC Gregory Renza Let's get started and welcome back everyone to the 2024 RBC Global Health Care Conference. My name is Greg Renza, one of the Biotechnology Research Analyst here at RBC and we're pleased to be joined with Inovio Pharmaceuticals now.
- 05/15/2024
|
Inovio Pharmaceuticals, Inc. (INO) The Citizens JMP Life Sciences Conference (Transcript)
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) The Citizens JMP Life Sciences Conference May 14, 2024 11:30 AM ET Company Participants Jacqueline Shea - CEO Conference Call Participants Roy Buchanan - Citizens JMP Roy Buchanan Everybody again for joining Citizens JMP Life Science Conference. My name's Roy Buchanan, I'm a biotech research analyst.
- 05/14/2024
|
Inovio Pharmaceuticals, Inc. (INO) Q1 2024 Earnings Call Transcript
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Mark Twyman - Chief Commercial Officer Peter Kies - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Roy Buchanan - JMP Anish Nikhanj - RBC Capital Markets Roger Song - Jefferies Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the INOVIO First Quarter 2024 Financial Results Conference Call.
- 05/13/2024
|
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
- BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papillomatosis (RRP) Planning initiation of confirmatory trial for INO-3107 based on FDA feedback Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM (toripalimab-tpzi) as a potential treatment for oropharyngeal squamous cell carcinoma (OPSCC) based on FDA feedback Balance sheet strengthened with underwritten offering of common stock and pre-funded warrants completed in April 2024 Cash runway projected into third quarter of 2025 PLYMOUTH MEETING, Pa. , May 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2024 and provided an update on recent company developments.
- 05/13/2024
|
This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy?
- Inovio Pharmaceuticals' former two leading candidates both fell flat. The company is seeking approval for another product following positive clinical results.
- 05/05/2024
|
INOVIO Reports Inducement Grants Under Inducement Plan
- PLYMOUTH MEETING, Pa. , May 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to two newly hired employees under its 2022 Inducement Plan (the "Inducement Plan").
- 05/01/2024
|
INOVIO to Participate in Upcoming Investor Conferences in May
- PLYMOUTH MEETING, Pa. , April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that management will participate in the following investor conferences during the month of May: The Citizens JMP Life Sciences Conference Date: Tuesday, May 14, 2024 Time: 11:30 AM ET Presenter: Dr. Jacqueline Shea, President & CEOFormat: Fireside Chat RBC Capital Markets 2024 Global Healthcare Conference Date: Wednesday, May 15, 2024 Time: 10:00 AM ET Presenter: Dr. Jacqueline Shea, President & CEOFormat: Fireside Chat H.C.
- 04/29/2024
|
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024
- PLYMOUTH MEETING, Pa. , April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2024 financial results will be released after the market close on May 13, 2024.
- 04/29/2024
|
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- PLYMOUTH MEETING, Pa. , April 15, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share and pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of $7.692 per pre-funded warrant, in each case before underwriting discounts and commissions.
- 04/15/2024
|
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
- PLYMOUTH MEETING, Pa. , March 26, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2, 2024.
- 03/26/2024
|
Call Traders Swarm Heavily Shorted Pharma Stock
- Options bulls are blasting Inovio Pharmaceuticals Inc (NASDAQ:INO) after Jefferies hiked its price target to $8 from $4.50 on Friday.
- 03/11/2024
|
Does Inovio (INO) Have the Potential to Rally 122.92% as Wall Street Analysts Expect?
- The consensus price target hints at a 122.9% upside potential for Inovio (INO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 03/08/2024
|
Inovio Pharmaceuticals, Inc. (INO) Q4 2023 Earnings Call Transcript
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Mark Twyman - Chief Commercial Officer Peter Kies - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Company Roy Buchanan - Citizens Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen and welcome to the INOVIO Fourth Quarter and Year-End 2023 Financial Results Conference Call.
- 03/06/2024
|
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- Announced substantial progress with lead program, INO-3107, as potential treatment for Recurrent Respiratory Papillomatosis (RRP) Positive data announced from Phase 1/2 trial Orphan Drug Designation granted by European Union Breakthrough Therapy Designation granted by U.S. Food and Drug Administration (FDA) Received FDA feedback that data from completed Phase 1/2 trial can be used to submit Biological License Application (BLA) under accelerated approval program Announced plan to submit BLA to FDA under accelerated approval program in second half of 2024 Announced clinical collaboration and supply agreement with Coherus BioSciences to advance development of INO-3112 in combination with LOQTORZI™ (toripalimab-tpzi) Combination therapy to be evaluated in a planned Phase 3 trial in patients with locoregionally advanced, high-risk, HPV-16/18-positive throat cancer Clinical trial design submitted to FDA in first quarter 2024; feedback expected in second quarter Reported positive Phase 1b results for INO-4201 as a potential Ebola booster vaccine for rVSV-ZEBOV (Ervebo®) Prioritized pipeline and reduced 2023 operating expenses by 48% from 2022 Ended 2023 with $145.3 million in cash, cash equivalents, and short-term investments Projects cash runway into second quarter 2025 Management will host conference call today at 4:30 p.m. ET PLYMOUTH MEETING, Pa.
- 03/06/2024
|
Wall Street Analysts Predict a 146.39% Upside in Inovio (INO): Here's What You Should Know
- The mean of analysts' price targets for Inovio (INO) points to a 146.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 02/21/2024
|
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
- PLYMOUTH MEETING, Pa. , Feb. 21, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that fourth quarter and year-end 2023 financial results will be released after the market close on March 6, 2024.
- 02/21/2024
|
Inovio (INO) Moves 17.4% Higher: Will This Strength Last?
- Inovio (INO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 02/12/2024
|
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- PLYMOUTH MEETING, Pa. , Feb. 7, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.
- 02/07/2024
|
INOVIO Reports Inducement Grant Under Inducement Plan
- PLYMOUTH MEETING, Pa. , Feb. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
- 02/02/2024
|
How Much Upside is Left in Inovio (INO)? Wall Street Analysts Think 223.72%
- The average of price targets set by Wall Street analysts indicates a potential upside of 223.7% in Inovio (INO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 01/30/2024
|
Why Is Inovio Pharmaceuticals (INO) Stock Down Today?
- Inovio Pharmaceuticals (NASDAQ: INO ) stock is taking a beating on Wednesday as the biotechnology company prepares for a reverse stock split. The company's shares will undergo a one-for-12 reverse stock split.
- 01/24/2024
|
Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why
- Inovio Pharma (INO) surges 134% in a month, mainly due to its plans to submit a regulatory application seeking approval of its lead candidate, INO-3107, in the second half of 2024 to treat RRP.
- 01/12/2024
|
The 3 Most Undervalued Biotech Stocks to Buy: November 2023
- These companies in the biotechnology sector are doing incredible work and achieving wonderful developments. The result is not not only growth and profit for the companies, but they are also offering excellent and efficient solutions for the health of each one of us.
- 11/14/2023
|
Inovio Pharmaceuticals, Inc. (INO) Q3 2023 Earnings Call Transcript
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacque Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Mark Twyman - Chief Commercial Officer Conference Call Participants Roger Song - Jefferies Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen and welcome to the Inovio Third Quarter 2023 Financial Results Conference Call.
- 11/09/2023
|
Inovio shares rise after positive FDA feedback on RRP treatment candidate
- Biotechnology company Inovio saw its shares jump after the US FDA communicated that data from Inovio completed Phase 1/2 trial of INO-3107 for treating Recurrent Respiratory Papillomatosis (RRP) could support the submission of a Biological License Application (BLA) for review under the FDA's accelerated approval program. Shares of the company gained around 54% on Tuesday in midday New York trading.
- 10/10/2023
|
Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 25th Annual Global Investment Conference (Transcript)
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 25th Annual Global Investment Conference Call September 12, 2023 4:30 PM ET Company Participants Jacqueline Shea - President and Chief Executive Officer Conference Call Participants Li Chen - H.C.
- 09/12/2023
|
Inovalis: Orange You Glad You Stayed Away?
- We gave Inovalis REIT our first review in December 2022. We noted that the NAV estimates were optimistic and crystallization of that value was improbable in the short term. We review where the REIT stands after losing its largest tenant.
- 06/28/2023
|
Inovio Pharmaceuticals, Inc. (INO) Jefferies Healthcare Conference 2023 (Transcript)
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Jefferies Healthcare Conference 2023 June 9, 2023 8:00 PM ET Company Participants Jacqueline Shea - President & CEO Michael Sumner - CMO Conference Call Participants Roger Song - Jefferies Roger Song Welcome, everyone, for last day, day three, 2023, Jeffrey's Healthcare Conference. My name is Roger Song.
- 06/09/2023
|
INOVIO to Present at the 2023 Jefferies Healthcare Conference
- PLYMOUTH MEETING, Pa. , May 25, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO, and Dr. Michael Sumner, CMO, will present at the 2023 Jefferies Healthcare Conference.
- 05/25/2023
|
INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up
- INOVIA (INO) shares surge 12% in the after-market hours, when its drug for treating a rare respiratory tract disease, INO-3107, receives orphan drug designation from the European Commission.
- 05/24/2023
|
Inovio Pharmaceuticals, Inc. (INO) 2023 RBC Capital Markets Global Healthcare Conference (Transcript)
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) 2023 RBC Capital Markets Global Healthcare Conference May 16, 2023 4:05 PM ET Company Participants Greg Renza - Biotechnology Equity Research Analyst, RBC Conference Call Participants Jacqueline Shea - President & CEO Greg Renza Great. So welcome back to the 2023 RBC Global Healthcare Conference.
- 05/17/2023
|
All You Need to Know About Inovio (INO) Rating Upgrade to Buy
- Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 05/15/2023
|
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates
- Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.36 per share a year ago.
- 05/10/2023
|
Penny Stocks To Buy? 10 Under $1 To Watch This Week
- Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?
- 04/19/2023
|
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
- Merck's decision to pay top dollar for a late-stage asset is sparking a wave of bargain buying in biotech today. Agenus, Inovio Pharmaceuticals, and Roivant Sciences are three of the biggest beneficiaries of the industrywide trend.
- 04/17/2023
|
Penny Stocks To Buy? 7 Under $1 To Watch This Week
- Penny stocks to watch trading for pennies this week. The post Penny Stocks To Buy?
- 04/17/2023
|
Why Inovio Pharmaceuticals' Shares Jumped on Thursday
- Inovio's shares are down more than 43% this year. The company said it has enough cash to last into the first quarter of 2025.
- 04/13/2023
|
Top Penny Stocks To Buy Now? 10 To Watch Under $5
- 10 Penny stocks under $5 to watch right now The post Top Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/13/2023
|
Why Shares of Inovio Pharmaceuticals Were Down Tuesday
- Inovio said it has enough cash to fund operations into the first quarter of 2025. The company focuses on DNA medicines to treat HPV diseases, cancer, and infectious diseases.
- 04/04/2023
|
INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference
- PLYMOUTH MEETING, Pa. , March 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D.
- 03/03/2023
|
Inovio Pharmaceuticals, Inc. (INO) Q4 2022 Earnings Call Transcript
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Thomas Hong - Manager-Investor Communications Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Charlie Young - Bank of America Yi Chen - H.C. Wainwright Operator Good afternoon, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2022 Financial Results Conference Call.
- 03/01/2023
|
Inovio Pharmaceuticals (INO) Reports Q4 Loss, Lags Revenue Estimates
- Inovio (INO) delivered earnings and revenue surprises of -31.25% and 72.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2023
|
2 Stocks to Sell or Remove From Your Watchlist in 2023
- Both stocks soared during the coronavirus vaccine race, but their time has passed.
- 02/28/2023
|
Are Penny Stocks on Your February Watchlist? 3 Reasons to Buy
- Should penny stocks be on your watchlist? The post Are Penny Stocks on Your February Watchlist?
- 02/06/2023
|
3 Sorry Pharma Stocks to Sell in February Before It's Too Late
- Pharmaceutical stocks have been relatively subdued in the last 12 months. During this period, the S&P 500 Pharmaceutical Industry index has trended higher by 3.5%.
- 02/01/2023
|
ETON Up as FDA Accepts NDA for Dehydrated Alcohol Injection
- Eton (ETON) gains as the its new drug application (NDA) for dehydrated alcohol injection for methanol poisoning is accepted for review by the FDA.
- 01/12/2023
|
3 Stocks to Avoid Right Now
- Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective.
- 11/17/2022
|
Buying Biotech Penny Stocks? 3 Things to Look For
- Are biotech penny stocks on your buy list right now The post Buying Biotech Penny Stocks? 3 Things to Look For appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 11/10/2022
|
Inovio Pharmaceuticals, Inc. (INO) Q3 2022 Earnings Call Transcript
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Thomas Hong – Manager-Investor Communications Jacque Shea – President and Chief Executive Officer Michael Sumner – Chief Medical Officer Peter Kies – Chief Financial Officer Conference Call Participants Hartaj Singh – Oppenheimer & Company Operator Good day and welcome to the Inovio Third Quarter 2022 Results Conference Call. [Operator instructions] Please note that this event is being recorded.
- 11/08/2022
|
Best Penny Stocks To Buy? 7 Short Squeeze Stocks To Watch Now
- Short squeeze stocks to watch right now. The post Best Penny Stocks To Buy?
- 11/02/2022
|
Why Inovio Pharmaceuticals Stock Zoomed Nearly 6% Higher Today
- The biotech is ceasing its internally funded efforts to develop a heterologous coronavirus booster.
- 10/28/2022
|
Why Inovio Pharmaceuticals' Shares Jumped 17.31% on Monday
- The stock jumped Monday despite no news from the company.
- 10/17/2022
|
Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 24th Annual Global Investment Conference (Transcript)
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 24th Annual Global Investment Conference September 12, 2022 7:00 AM ET Company Participants Jacqueline Shea - President and CEO Conference Call Participants Brooke Katsof - H.C.
- 09/12/2022
|
1 Green Flag and 1 Red Flag For Inovio Pharmaceuticals
- Can the company still count on its coronavirus-related efforts?
- 09/11/2022
|
Why Inovio Pharmaceuticals Is Gaining Today
- Its newly announced cost-saving measures are getting a warm reception.
- 08/10/2022
|
Inovio Pharmaceuticals (INO) Reports Q2 Loss, Tops Revenue Estimates
- Inovio (INO) delivered earnings and revenue surprises of -53.33% and 264.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2022
|
Inovio Pharmaceuticals, Inc. (INO) CEO Jacqueline Shea on Q2 2022 Results - Earnings Call Transcript
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Thomas Hong - IR Jacqueline Shea - CEO, President & Director Michael Sumner - Chief Medical Officer David Liebowitz - SVP, Clinical Development Jeffrey Skolnik - SVP, Clinical Development Peter Kies - CFO Conference Call Participants Alexandria Hammond - Bank of America Merrill Lynch Gregory Renza - RBC Capital Markets Jiale Song - Jefferies Eka Gigauri - Oppenheimer Raghuram Selvaraju - H.C. Wainwright & Co. Yi Chen - H.C.
- 08/09/2022
|
Two Appealing Biotech Stocks for Two Distinct investors
- Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles
- 08/08/2022
|
1 Beaten-Down Growth Stock To Avoid Like the Plague
- The last few years haven't been kind to Inovio Pharmaceuticals.
- 07/24/2022
|
After Slashing Costs, Is Inovio a Buy?
- It's betting on success as a vaccine latecomer.
- 07/22/2022
|
RBC Capital Lowers Inovio Price Target As It Awaits This
- RBC Capital Markets has lowered the price target on Inovio Pharmaceuticals Inc (NASDAQ: INO) to $4 from $5 with a Sector Perform rating. The analysts updated the model to reflect the evolution of the programs to date and as new leadership gained traction since the CEO change in.
- 07/19/2022
|
Inovio to reduce its workforce by 18%
- Inovio Pharmaceuticals Inc. INO, -6.60% said Tuesday that it plans to reduce its full-time workforce by 18% and its contractor workforce by 86% in an effort to extend its cash runway. The company had 317 full-time employees in 2021.
- 07/19/2022
|
Why Inovio Pharmaceuticals Stock Topped the Market on Monday
- The appointment of a new top executive clearly meets with investor approval.
- 06/27/2022
|
7 Monkeypox Stocks That May Take Off in Q2
- SIGA Technologies (SIGA) may lead on the list of monkeypox stocks that could soar, but Bavarian Nordic seems to be leading the sales race. The post 7 Monkeypox Stocks That May Take Off in Q2 appeared first on InvestorPlace.
- 06/09/2022
|
Inovio Pharmaceuticals, Inc. (INO) CEO Jacqui Shea Present at Jefferies 2022 Global Healthcare Conference (Transcript)
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Jefferies 2022 Global Healthcare Conference June 8, 2022 1:00 PM ET Company Participants Jacqui Shea - CEO Jeffrey Skolnik - CMO Conference Call Participants Roger Song - Jefferies Roger Song Good afternoon, everyone. Welcome to Jefferies Global Healthcare Conference day one afternoon.
- 06/08/2022
|
INOVIO Pharmaceuticals (INO) Stock Price: Why It Rose Over 14% Today
- The stock price of INOVIO Pharmaceuticals Inc (NASDAQ: INO) increased by over 14% during intraday trading today. This is why.
- 05/27/2022
|
Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR
- Are these penny stocks to buy or avoid right now? The post Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/27/2022
|
7 Monkeypox Stocks to Watch Right Now
- Wondering what are the best monkeypox stocks to watch? Here are the companies producing vaccines to help fight the spread of the virus.
- 05/24/2022
|
Why Inovio Pharmaceuticals Stock Is Rising Today
- Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher Monday amid increasing monkeypox concerns. A monkeypox outbreak has been reported in at least a dozen countries.
- 05/23/2022
|
6 Stocks To Watch Amid Monkeypox Outbreak
- A Monkeypox outbreak has been reported in several European countries, two cases in Canada and one confirmed case in a man from Massachusetts. What's going on?
- 05/20/2022
|
Is This Vaccine Stock in Trouble -- or Ready for a Rebound?
- Inovio may be at a turning point.
- 05/13/2022
|
INO Stock Plunges 25% as Inovio Pharmaceuticals Swaps Vaccine Focus
- Inovio Pharmaceuticals has halted its Covid-19 progress to focus on a booster. Here's why this news is unlikely to boost INO stock.
- 05/11/2022
|
Inovio lets go of CEO, to stop work on COVID-19 vaccine and instead focus on booster
- Inovio Pharmaceuticals Inc.'s INO, +5.06% stock tumbled 21.7% in premarket trading on Wednesday, the day after the company said it will discontinue its work on a COVID-19 vaccine and will instead focus only on developing a booster. Inovio also said it has replaced CEO Joseph Kim.
- 05/11/2022
|
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Lags Revenue Estimates
- Inovio (INO) delivered earnings and revenue surprises of -28.57% and 56.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/10/2022
|
Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022
- Primary and secondary endpoints met in late-stage REVEAL 1 which used VGX-3100 for women with HSIL. Results form the second late-stage study REVEAL 2, using VGX-3100 for women with HSIL, expected in Q4 of 2022.
- 04/15/2022
|
Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Oppenheimer's 32nd Annual Healthcare Conference (Transcript)
- Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Oppenheimer's 32nd Annual Healthcare Conference (Transcript)
- 03/15/2022
|
SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
- SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
- 03/07/2022
|
Why Inovio Stock Tumbled on a Good Day for the Market Wednesday
- The company's Q4 results didn't provide a lot of fuel for optimism.
- 03/02/2022
|
Inovio Pharmaceuticals, Inc. (INO) CEO Dr. Joseph Kim on Q4 2021 Results - Earnings Call Transcript
- Inovio Pharmaceuticals, Inc. (INO) CEO Dr. Joseph Kim on Q4 2021 Results - Earnings Call Transcript
- 03/01/2022
|
Could Inovio Pharmaceuticals Become the Next Moderna?
- It was certainly a possibility in 2020.
- 02/02/2022
|
2 Stocks to Avoid Like the Plague in 2022
- These companies wouldn't be worth a second look, even in a less volatile market.
- 01/29/2022
|
LABU - A Compelling Biotech Trade
- LABU - A Compelling Biotech Trade
- 01/26/2022
|
Inovio Undervalued On Potential 2022 Catalyst
- Inovio's stock price is back near pre-Covid levels. It is nearing commercialization of its HPV dysplasia vaccines. It might even still succeed in the Covid vaccine game.
- 01/26/2022
|
Why This Analyst Has Increased Confidence In Inovio Pharmaceuticals
- Following the recent pullback in Inovio Pharmaceuticals Inc.'s (NASDAQ:INO) shares, the stock valuation seems to have been stripped of most of the remaining COVID-19 value, according to BofA Securities. The Inovio Pharmaceuticals Analyst: Geoff Meacham upgraded the rating for Inovio Pharmaceuticals from Underperform to Neutral while raising the price target from $8 to $10.
- 01/21/2022
|
Down 21.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)
- The heavy selling pressure might have exhausted for Inovio (INO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 01/11/2022
|
Better Vaccine Stock: Ocugen vs. Inovio Pharmaceuticals
- Both companies could become notable latecomers in the coronavirus vaccine market.
- 01/11/2022
|
Is A Rise Imminent For Inovio Pharmaceuticals Stock After A Large 17% Fall In A Month
- The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large fall of 17% over the last month, while it is down 8% over the last week. This can be attributed to the spread of the new Covid-19.
- 12/17/2021
|
3 Ultra-Popular Stocks Expected to Increase Sales 981% to 5,569% in 2022
- Jaw-dropping sales growth doesn't always tell investors the full story.
- 12/15/2021
|
Here's Why These 3 COVID-19 Vaccine Stocks Got Crushed This Week
- These second-tier COVID-19 vaccine players plunged due to fears about the potential impacts of the omicron variant.
- 12/03/2021
|
Is Inovio Stock Set to Rebound?
- Inovio plans to tackle the omicron variant.
- 12/02/2021
|
Battle of the COVID Vaccine Contenders: Inovio vs. Ocugen
- Both vaccine makers still have big hurdles to jump.
- 11/21/2021
|
3 Vaccine Latecomers That Could Double Your Money
- Catalysts for the stocks are just ahead.
- 11/21/2021
|
Inovio Pharmaceuticals: Forget The COVID Pump, And Keep Your Eye On The Oncology Side
- Inovio has been on a rollercoaster ride since the start of the pandemic, and its current aspirations are tied largely to the development of antiviral vaccines. With huge R&D cash burn, the stakes have never been higher for Inovio.
- 11/18/2021
|
5 Biotech Stocks To Check Out In The Stock Market Now
- Could these top biotech stocks be worth investing in for the long term?
- 11/18/2021
|
Does This News Make Inovio Pharmaceuticals Stock a Buy?
- The company is closer than ever to launching its coronavirus vaccine -- but will it be good enough to make the stock worth purchasing?
- 11/17/2021
|
Why Inovio Stock Is Rising Today
- The company received a green light to begin a U.S. phase 3 study of its COVID-19 vaccine candidate.
- 11/10/2021
|
Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Q3 2021 Results - Earnings Call Transcript
- Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Q3 2021 Results - Earnings Call Transcript
- 11/09/2021
|
Inovio Pharmaceuticals (INO) Reports Q3 Loss, Tops Revenue Estimates
- Inovio (INO) delivered earnings and revenue surprises of 12.12% and 53.68%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/09/2021
|
Inovio Pharmaceuticals Sees A Bounce Off Support After COVID-19 Vaccine News
- Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares are trading higher Tuesday after the FDA removed a hold on the company's late-stage COVID-19 vaccine trial in the U.S. Inovio Pharmaceuticals is trading up 4.60% at $7.05 at market close Tuesday.
- 11/09/2021
|
Why Shares of Inovio Pharmaceuticals Rallied Today
- The FDA lifted its hold on the next step of its COVID-19 vaccine trial, although that doesn't mean much at this point.
- 11/09/2021
|
INO Stock: The Covid-19 Vaccine News Helping Inovio Power Higher
- Inovio Pharmaceuticals (INO) stock is pushing higher on Tuesday after providing investors with an update on its Covid-19 vaccine. The post INO Stock: The Covid-19 Vaccine News Helping Inovio Power Higher appeared first on InvestorPlace.
- 11/09/2021
|
FDA Lifts Clinical Hold On Inovio's COVID-19 Vaccine Trial
- The FDA has lifted a partial clinical hold on a late-stage trial of Inovio Pharmaceuticals Inc's (NASDAQ: INO) COVID-19 vaccine in the U.S. Inovio said it now has the authorization to proceed with the trial in the U.S. after 14 months.
- 11/09/2021
|
Inovio says the FDA lifted its 'hold' on the Phase 3 clinical trial for its COVID-19 shot
- Shares of Inovio Pharmaceuticals Inc. INO, +0.75% gained 5.9% in premarket trading on Tuesday after the company said it can move forward with the Phase 3 clinical trial for its experimental COVID-19 shot now that the Food and Drug Administration has lifted its partial clinical hold. Inovio had announced the partial clinical hold in September of last year.
- 11/09/2021
|
AstraZeneca's Medimmune Terminates DNA Cancer Vaccine Program With Inovio
- MedImmune Limited, a unit of AstraZeneca Plc (NASDAQ: AZN), has notified Inovio Pharmaceuticals Inc (NASDAQ: INO) to terminate the DNA cancer vaccine development program agreement. Under the agreement, MedImmune acquired exclusive rights to INO-3112 immunotherapy, renamed MEDI0457, targeting cancers caused by human papillomavirus types 16 and 18.
- 11/01/2021
|
INO Stock: Why The Price Increased This Past Week
- The stock price of INOVIO (NASDAQ:INO) increased by over 7% this past week. This is why it happened.
- 10/15/2021
|
Will Inovio Pharmaceuticals Stock See Higher Levels After A 6% Rise In A Week?
- The stock price of Inovio Pharmaceutic, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, reached its 52-week high levels of around $19 in February this year, before a large sell-off resulted in INO stock falling to levels of around $6 in April.
- 10/14/2021
|
4 Growth Stocks With 187% to 434% Upside, According to Wall Street
- Based on analysts' loftiest price targets, these companies could nearly triple or potentially quintuple investors' money over the next year.
- 10/13/2021
|
INOVIO Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800
- PLYMOUTH MEETING, Pa., Oct. 12, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the online preprint publication in MedRxiv of Phase 1 clinical data on homologous boosting of its COVID-19 DNA vaccine candidate, INO-4800.
- 10/12/2021
|
Is This The Turning Point for Inovio?
- The biotech's streak of bad luck may be about to end, but risks remain.
- 10/06/2021
|
Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Cantor 2021 Global Healthcare Conference (Transcript)
- Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Cantor 2021 Global Healthcare Conference (Transcript)
- 09/30/2021
|
INOVIO to Present Three Posters at IDWeek 2021
- PLYMOUTH MEETING, Pa., Sept. 29, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, will present three posters at IDWeek 2021, taking place virtually from September 29 th - October 3 rd.
- 09/29/2021
|
Is Vaccine Latecomer Inovio Making a Comeback?
- Its new plan for phase 3 trials is advancing.
- 09/29/2021
|
Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit Conference (Transcript)
- Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit Conference (Transcript)
- 09/21/2021
|
5 COVID Vaccine Stocks With Late-Stage Candidates You'll Want to Watch
- Their vaccines could be late to the party. But the stocks might still be big winners.
- 09/18/2021
|
INO Stock: 3.08% Increase Explanation
- The stock price of INOVIO (NASDAQ: INO) increased by 3.08% today. This is why it happened.
- 08/26/2021
|
Why Inovio Stock Is Jumping Today
- The vaccine maker received some good news from Brazil.
- 08/26/2021
|
Inovio Pharmaceuticals Stock Nears End Of Technical Pattern
- Inovio Pharmaceuticals Inc. (NASDAQ:INO) shares are trading higher Thursday after the company announced it received regulatory authorization from Brazil's ANVISA to initiate the global Phase 3 segment of its Phase 2/3 trial for INO-4800. Inovio Pharmaceuticals stock was up 9.3% at $9.22 at last check.
- 08/26/2021
|
Inovio To Start Global Late-Stage COVID-19 Vaccine Trial
- The regulatory authority of Brazil has signed off Inovio Pharmaceuticals Inc's (NASDAQ: INO) global Phase 3 segment of its INNOVATE Phase 2/3 trial for INO-4800, DNA COVID-19 vaccine candidate. Related Content: Inovio's DNA COVID-19 Vaccine Candidate Triggers Immune Response In Pivotal Study.
- 08/26/2021
|
5 Popular Stocks Billionaires Couldn't Sell Fast Enough in the Second Quarter
- These widely held stocks were on successful money managers' chopping blocks in Q2.
- 08/20/2021
|
Why Dynavax, Novavax, and Inovio Stocks Sank This Week
- Investors appeared to be rattled by the U.S. government's decision to move forward with booster doses of mRNA vaccines.
- 08/20/2021
|
3 Scary COVID Stocks to Avoid
- Our Fool roundtable picks three COVID stocks they think are dangerous at these prices.
- 08/17/2021
|
Watch Out: Inovio Pharmaceuticals Is Heating Up
- Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares are trading higher Thursday alongside other vaccine maker stocks. Stocks have been trading higher recently as the COVIS-19 delta variant has been spreading throughout the U.S. Inovio Pharmaceuticals was up 13.45% at $9.70 at last check Thursday.
- 08/12/2021
|
Former Penny Stocks To Watch After Merck's (MRK) Latest FDA Win
- Merck's FDA and coronavirus vaccine news sparked momentum in biotech stocks today. Here are 4 to watch.
- 08/12/2021
|
Why Inovio Pharmaceuticals Is Plunging Today
- Solid business developments did not please investors.
- 08/10/2021
|
Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Q2 2021 Results - Earnings Call Transcript
- Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Q2 2021 Results - Earnings Call Transcript
- 08/09/2021
|
Recap: Inovio Pharmaceuticals Q2 Earnings
- Shares of Inovio Pharmaceuticals (NASDAQ:INO) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 95.00% year over year to ($0.39), which missed the estimate of ($0.25).
- 08/09/2021
|
INOVIO Reports Second Quarter 2021 Financial Results
- PLYMOUTH MEETING, Pa., Aug. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results for the quarter ended June 30, 2021.
- 08/09/2021
|
Why Inovio Stock Is Jumping Today
- Chinese regulators approved the initiation of two new clinical studies featuring Inovio's COVID-19 vaccine candidate, INO-4800.
- 08/09/2021
|
INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate
- PLYMOUTH MEETING, Pa. and SUZHOU, China, Aug. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it has received regulatory allowance for two clinical trials investigating heterologous boosting with INO-4800, its DNA vaccine candidate for COVID-19, through partner and trial-sponsor Advaccine Biopharmaceuticals Suzhou Co., Ltd.
- 08/09/2021
|
What Does the Delta Variant Mean for Inovio Pharmaceuticals' Stock?
- Its vaccine candidate might be too far behind to matter.
- 08/05/2021
|
INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease
- PLYMOUTH MEETING, Pa., Aug. 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that the company has dosed the first Phase 2 trial subject in its quest to develop the first vaccine against the Middle East Respiratory Syndrome (MERS).
- 08/04/2021
|
Former Biotech Penny Stocks Seeing Explosive Moves In 2021
- Are penny stocks worth it? Take a look at these 3 seeing explosive moves this year.
- 08/02/2021
|
Can Last Year's Biggest Vaccine Stocks Crush the Market Again?
- These players delivered triple- and quadruple-digit gains.
- 08/02/2021
|
INOVIO to Report Second Quarter 2021 Financial Results on August 9, 2021
- PLYMOUTH MEETING, Pa., July 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that second quarter 2021 financial results will be released after the market close on August 9, 2021.
- 07/26/2021
|
Is Inovio Pharmaceuticals Primed For a Comeback?
- The past 12 months have been tough on the vaccine maker.
- 07/22/2021
|
5 Heavily Short-Sold Stocks That Won't Squeeze
- Hoping for a short squeeze? These stocks aren't your best bet.
- 07/18/2021
|
3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street
- Analysts' high-water price targets imply some serious gains for these companies.
- 07/15/2021
|
Bear of the Day: Inovio Pharmaceuticals (INO)
- Is it too late to buy this coronavirus vaccine stock?
- 07/12/2021
|
Here's Why Inovio Pharmaceuticals Soared 23% In June
- Encouraging news reversed what had been a steep sell-off for the clinical-stage biotech.
- 07/08/2021
|
With COVID-19 Variant Threats Rising, Why Are Vaccine Stocks Falling?
- Stock markets moved slightly higher despite general worries.
- 07/07/2021
|
Inovio Has 4 Sources Of Potential Value
- DNA plasmid technology has many applications. Inovio's Covid-19 vaccine may still have a global market.
- 06/22/2021
|
Inovio Pharmaceuticals Could See a Boost from Covid-19 Partnerships
- Some say INO stock could be the target of a short squeeze, but Inovio's Covid-19 vaccine program should be a sufficient reason to invest. The post Inovio Pharmaceuticals Could See a Boost from Covid-19 Partnerships appeared first on InvestorPlace.
- 06/21/2021
|
Should You Buy Biotech ETFs Now?
- Biotech stocks are rallying this month; can the trend continue?
- 06/16/2021
|
Why Inovio Stock Is Sinking Today
- Investors appear to be taking some profits after yesterday's huge gain.
- 06/10/2021
|
Why Inovio Stock Looks Ready To Break Out, Make Bullish Reversal
- Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares were trading higher Wednesday as retail traders continue to push high short interest stocks higher. The stock saw above average volume and was trending on social media sites throughout the day.
- 06/09/2021
|
INO Stock: 2 Big Reasons Inovio Pharmaceuticals Is Shooting Higher Today
- Today, INO stock is soaring amid a recently announced expanded partnership for its Covid-19 vaccine and potential short squeeze implications. The post INO Stock: 2 Big Reasons Inovio Pharmaceuticals Is Shooting Higher Today appeared first on InvestorPlace.
- 06/09/2021
|
Inovio, Advaccine to Share $100M in Cost for Late-Stage COVID-19 Vaccine Trial
- Inovio Pharmaceuticals Inc (NASDAQ: INO) has expanded its partnership with Advaccine Biopharmaceuticals Suzhou Co Ltd to jointly conduct a global Phase 3 part of the ongoing Phase 2/3 trial, INNOVATE, assessing its DNA COVID-19 vaccine candidate. The trial will evaluate the safety and efficacy of INO-4800 in a two-dose regimen (2.0 mg), administered one month apart, in two-to-one randomization in subjects 18 years and older across several countries, primarily in Latin America and Asia.
- 06/08/2021
|
INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800
- PLYMOUTH MEETING, Pa., June 8, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced an expansion of its previously announced partnership with Advaccine Biopharmaceuticals Suzhou Co., Ltd.
- 06/08/2021
|
These Vaccine Latecomers Could Still Win Big. Here's How
- The key is standing out from the crowd.
- 06/07/2021
|
Why Inovio Pharmaceuticals Stock Perked Up in May
- The biotech's pan-COVID-19 vaccine caught the eye of investors last month.
- 06/06/2021
|
Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine Program
- PLYMOUTH MEETING, Pa., June 3, 2021 /PRNewswire/ -- Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announced today positive preliminary results of its ongoing first-in-human trial.
- 06/03/2021
|
Is It Too Late to Buy Inovio Pharmaceuticals Stock?
- This troubled coronavirus vaccine developer has created far more woes than joys for investors.
- 06/03/2021
|
INOVIO Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Jefferies 2021 Virtual Healthcare Conference (Transcript)
- INOVIO Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Jefferies 2021 Virtual Healthcare Conference (Transcript)
- 06/01/2021
|
New to Investing? 3 Beginner Mistakes to Avoid
- There are plenty of things you'll learn through your experiences as an investor, but these are ones to learn as soon as possible.
- 06/01/2021
|
7 Former Pandemic Stocks to Buy That Are No Longer Running Hot
- The pandemic bolstered many stocks to buy. But with cases fading, this narrative is now questionable.
- 05/26/2021
|
INOVIO to Present at the Jefferies 2021 Virtual Healthcare Conference
- PLYMOUTH MEETING, Pa., May 25, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO) a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, announced today that Dr. Joseph Kim, President and CEO, is scheduled to participate in a fireside chat and 1x1 investor meetings at the Jefferies 2021 Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:00 PM EDT.
- 05/25/2021
|
Ocugen vs. Inovio: Where Is the Smart Money Going?
- They're both seeking share in the vaccine market.
- 05/23/2021
|
Inovio's Latest COVID Vaccine Results: Too Little, Too Late?
- Maybe not -- especially outside of the U.S.
- 05/21/2021
|
1 Coronavirus Vaccine Company to Avoid Like The Plague in May (and Beyond)
- This biotech's prospects look dim.
- 05/13/2021
|
Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Q1 2021 Results - Earnings Call Transcript
- Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Q1 2021 Results - Earnings Call Transcript
- 05/10/2021
|
INO Stock: Over 3% Increase Pre-Market Explanation
- The stock price of INOVIO (NASDAQ:INO) increased by over 3% pre-market. This is why it happened.
- 05/10/2021
|
Inovio Pharmaceuticals: Once Bitten, Twice Shy
- Inovio's INO-4800 path forward remains ex-US. Expect an announcement on the FDA partial hold to be removed very soon. A spin-off opportunity is available and should be considered.
- 05/05/2021
|
INOVIO to Present at Upcoming Investor Conferences in May
- PLYMOUTH MEETING, Pa., May 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that INOVIO management will present at the following virtual investor conferences in May: Bank of America Merrill Lynch Health Care Conference Date: Tuesday, May 12, 2021 Time: 9:30 AM ET Presentation Format: Fireside Chat RBC Global Healthcare Conference Date: Tuesday, May 18, 2021 Time: 9:45 AM ET Presentation Format: Fireside Chat Live and archived versions of the virtual presentations will be available through the INOVIO Investor Relations Events page and may be accessed by visiting INOVIO's website at http://ir.inovio.com/investors/events/default.aspx.
- 05/04/2021
|
Can Inovio Recover From Its Huge Setback?
- It might be able to, although it won't be easy.
- 04/28/2021
|
INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021
- PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after the market close on May 10, 2021.
- 04/27/2021
|
5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street
- These tiny stocks could pack big-time return potential, if analysts are correct.
- 04/27/2021
|
Is There Any Hope for Inovio?
- Everything may depend on an early-stage program.
- 04/27/2021
|
Even as the Stock Market Rose Friday, Investors Got a Harsh Reminder
- There's real value in being a first-mover.
- 04/23/2021
|
4 Top Stock Trades for Monday: SNAP, INTC, HON, INO
- Snap, Intel, Honeywell and Inovio were our top stock trades for Monday. That said, let's look at how the charts are setting up now.
- 04/23/2021
|
Inovio sinks 26% after US government decides to discontinue funding for next phase of COVID-19 vaccine trial
- Inovio Pharmaceuticals shares were chopped down by nearly a third on Friday after the US government said it will discontinue funding for a late-phase trial of the company's COVID-19 vaccine candidate. The biotech company said it was informed that it will lose federal financial support for the phase three segment of its Innovate trial for INO-4800. The DNA vaccine candidate is aimed at preventing infection from SARS-CoV-2, the coronavirus behind the COVID-19 disease.
- 04/23/2021
|
Inovio Stock Collapses After U.S. Officials Pull Funding For Covid Vaccine Test
- Inovio Pharmaceuticals said Friday the Department of Defense pulled its funding for final-phase testing of the company's Covid vaccine and device, prompting INO stock to collapse. The post Inovio Stock Collapses After U.S. Officials Pull Funding For Covid Vaccine Test appeared first on Investor's Business Daily.
- 04/23/2021
|
Why Inovio Stock Is Crashing Today
- The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.
- 04/23/2021
|
Why Novavax, Inovio, and Protara Are Moving Today
- Novavax, Inc. (NASDAQ: NVAX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and Protara Therapeutics, Inc. (NASDAQ: TARA) are among the biotech movers Friday. Novavax Moves On Mid-stage Malaria Vaccine Data: Novavax, which is in the final legs of completing the COVID-19 vaccine race, is moving on success in another arena.
- 04/23/2021
|
Inovio Dives After Government Backs Out of Covid Vaccine Deal
- The biotech said the decision was based on the wide availability of shots in the U.S., although the Phase 3 trial of the drug will go forward abroad.
- 04/23/2021
|
Inovio stock plunges after U.S. government stops funding of Phase 3 trial of COVID-19 vaccine candidate
- Shares of Inovio Pharmaceuticals Inc. plunged 29.7% toward a 13-month low, enough to pace all premarket decliners Friday, after the company said the U.S. government has cut off funding for the Phase 3 trial of its COVID-19 vaccine candidate because vaccines are already broadly available. The company said it will continue with its work toward a Phase 3 trial, but is now planning a "predominantly ex-U.S." trial for its COVID-19 vaccine candidate, INO-4800.
- 04/23/2021
|
Inovio Stock Slumps After Plans To Exclude US For COVID-19 Vaccine Candidate's Global Trial
- Inovio Pharmaceuticals Inc (NASDAQ: INO) shares dived in the premarket in reaction to the company's plans for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800. Given the increasing availability of vaccines authorized for emergency use, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense in coordination with the Office of the Assistant Secretary of Defense for Health Affairs and the Defense Health Agency, will discontinue funding for the Phase 3 portion of the INNOVATE trial, while continuing to fund the completion of the ongoing Phase 2 part.
- 04/23/2021
|
INO Stock: Over 20% Decrease Pre-Market Explanation
- The stock price of Inovio Pharmaceuticals Inc (NASDAQ: INO) fell by over 20% pre-market. This is why it happened.
- 04/23/2021
|
INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800
- PLYMOUTH MEETING, Pa., April 23, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it is planning for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800.
- 04/23/2021
|
Here's the Dr. Fauci Statement That Could Mean Good News for Inovio
- It's all about the ultimate coronavirus vaccine.
- 04/21/2021
|
INO Stock: Over 15% Increase Intraday Explanation
- The stock price of Inovio Pharmaceuticals Inc (NASDAQ: INO) increased by over 15% during intraday trading. This is why it happened.
- 04/15/2021
|
INOVIO's COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern
- PLYMOUTH MEETING, Pa., April 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, and cancer, today announced the results of a study focusing on the human immune responses induced by INOVIO's DNA vaccine candidate for COVID-19, INO-4800, against variants of concern.
- 04/15/2021
|
Do Options Traders Know Something About Inovio (INO) Stock We Don't?
- Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.
- 04/12/2021
|
INOVIO INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inovio Pharmaceuticals Inc. - INO
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Inovio Pharmaceuticals Inc. (NasdaqGS: INO). On March 9, 2020 Citron Research published a statement highlighting the Company's “ludicrous and dangerous claim that they designed a [COVID-19] vaccine in 3 hours” and calling for an SEC investigation into the claims. That same day, the Com
- 04/09/2021
|
This 1 Element May Be Holding Inovio's Vaccine Back
- It has to do with game-changing technology.
- 04/02/2021
|
Down 40% From Recent Highs Can Inovio Pharmaceuticals Stock Rebound?
- We believe that Inovio Pharmaceuticals , a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, is a good buying opportunity at the present time. INO stock trades near $10 currently and it is, in fact, down 27% from its pre-Covid high of around $14.
- 03/24/2021
|
Inovio VGX-3100 HPV Data Adds To Conviction
- Inovio VGX-3100 HPV Data Adds To Conviction
- 03/23/2021
|
Inovio Has 'Bigger Value Drivers' Outside Of COVID-19 Vaccine Program: BofA Analyst
- Inovio Pharmaceuticals, Inc. (NASDAQ: INO), which has fallen behind in the COVID-19 vaccine race, has much to offer beyond a coronavirus vaccine, according to a BofA Securities analyst. The Inovio Analyst: Geoff Meacham initiated coverage of Inovio with a Neutral rating and $13 price target.
- 03/23/2021
|
DraftKings, GlaxoSmithKline, Netflix, Southwest and More Tuesday Afternoon Analyst Calls
- With the trading day about halfway over, the broad markets had pulled back slightly.
- 03/23/2021
|
Vaxart or Inovio: Which Is More Likely to Double Your Money?
- Let's look at what some of the smartest investors are saying.
- 03/21/2021
|
These 3 Vaccine Stocks May Be Post-Pandemic Winners
- Why? They're focusing on one of the biggest coronavirus problems.
- 03/20/2021
|
4 Heavily Short-Sold Stocks to Avoid Like the Plague
- Although these stocks are popular with the Reddit community, they're bad news.
- 03/16/2021
|
Can Inovio Pharmaceuticals Stock Recover After The Recent 25% Drop?
- The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large 27% drop over the last ten trading days, while it's down 14% over the last five trading days, but we believe the stock, after the.
- 03/04/2021
|
Why Inovio Stock Is Tanking Today
- Investors still appear to have doubts about two of the biotech's lead candidates.
- 03/02/2021
|
Why Inovio's Positive Q4 Update Didn't Impress Investors
- Better-than-expected top- and bottom-line results weren't enough.
- 03/02/2021
|
Inovio Pharmaceuticals' (INO) CEO Joseph Kim on Q4 2020 Results - Earnings Call Transcript
- Inovio Pharmaceuticals' (INO) CEO Joseph Kim on Q4 2020 Results - Earnings Call Transcript
- 03/02/2021
|
Inovio Reports Q4 Earnings Beat, Mixed REVEAL 1 Data And Coronavirus Vaccine Update
- Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are lower in after-hours trading in reaction to multiple catalysts. REVEAL 1 Study Reveals Mixed Results In Cervical Dysplasia: Inovio said a pivotal REVEAL 1 Phase 3 study of VGX-3100 in treating high-grade precancerous cervical dysplasia, caused by HPV-16 and/or HV-18 met primary and secondary endpoints among all evaluable subjects.
- 03/01/2021
|
Recap: Inovio Pharmaceuticals Q4 Earnings
- Shares of Inovio Pharmaceuticals (NASDAQ:INO) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 63.16% over the past year to ($0.14), which beat the estimate of ($0.22).
- 03/01/2021
|
Earnings Outlook For Inovio Pharmaceuticals
- On Monday, March 01, Inovio Pharmaceuticals (NASDAQ:INO) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
- 02/26/2021
|
Is a Surprise Coming for Inovio (INO) This Earnings Season?
- Inovio (INO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/26/2021
|
Qiagen, Inovio In Development Pact For VGX-3100 Companion Diagnostics
- Qiagen NV (NYSE: QGEN) and Inovio Pharmaceuticals Inc (NASDAQ: INO) expanded their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products using next-generation sequencing technology to complement Inovio's therapies. The initial project in this expanded collaboration focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from the clinical use of VGX-3100, INO's immunotherapy, to treat advanced cervical dysplasia associated with the human papillomavirus (HPV).
- 02/24/2021
|
INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia
- PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, Feb. 24, 2021 /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop...
- 02/24/2021
|
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
- Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/22/2021
|
Inovio (INO) to Report Q4 Earnings: What's in the Cards?
- On Inovio's (INO) fourth-quarter earnings call, investor focus will be on updates on the company's progress with the development of its COVID-19 vaccine candidate, INO-4800.
- 02/22/2021
|
Are Short-Sellers Right About Inovio?
- This straggler in the vaccine race is still facing some struggles -- but there are a couple of bright spots.
- 02/21/2021
|
Inovio Pharmaceuticals (INO) Dips More Than Broader Markets: What You Should Know
- Inovio Pharmaceuticals (INO) closed the most recent trading day at $13.84, moving -0.93% from the previous trading session.
- 02/19/2021
|
Better Coronavirus Stock: Inovio Pharmaceuticals vs. Vaxart
- The choice isn't easy, but simplicity may be the answer.
- 02/15/2021
|
Inovio Shares Rally As Oppenheimer Says Coronavirus Vaccine Developer Approaching Finish Line
- Shares of coronavirus vaccine developer Inovio Pharmaceuticals Inc (NASDAQ: INO) were surging Friday after a vote of confidence from the Street. Bullish Analyst, Fund Stake Prop Up Stock: Oppenheimer analyst Hartaj Singh initiated coverage of Inovio shares with an Outperform rating and $35 price target in a Thursday note.
- 02/12/2021
|
Why Inovio Pharmaceuticals Stock Is Soaring Today
- An analyst is really bullish about the biotech stock.
- 02/12/2021
|
Here's Why Disney, Inovio, Fisker, Aurora, Hyliion Are Moving
- One of the most common questions traders have about stocks is “Why Is It Moving?”. That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.
- 02/12/2021
|
INO Stock Price Increases Over 20% Pre-Market: Why It Happened
- The stock price of Inovio Pharmaceuticals Inc (NASDAQ: INO) is trading at over 20% pre-market as of 8:22 AM ET. This is why it happened.
- 02/12/2021
|
Could Inovio Pharmaceuticals Be a Millionaire-Maker Stock?
- Once a leader in the COVID-19 vaccine race, does this biotech have what it takes to deliver market-shattering returns?
- 02/12/2021
|
Is Now the Time to Buy Inovio Stock?
- Reddit investors are sure hyped up about shares of this biotech underdog. Should you be as well?
- 02/07/2021
|
Should I invest in Inovio Pharmaceuticals shares in February?
- In less than several weeks, Inovio Pharmaceuticals (NASDAQ: INO) shares have advanced from $8.8 to $19, and the current price stands around $15. Inovio Pharmaceuticals has signed an agreement with Advaccine Biopharmaceuticals, and the positive news is that BlackRock increased its ownership in this company.
- 02/02/2021
|
INO Stock Price Increases Over 12% Pre-Market: Why It Happened
- The stock price of Inovio Pharmaceuticals Inc (NASDAQ: INO) is trading at more than 12% pre-market today as of 8:51 AM. This is why it happened.
- 02/02/2021
|
10 Robinhood Stocks With the Highest Short Interest
- Pessimists have piled into these companies, but that doesn't seem to be fazing millennial investors one bit.
- 01/31/2021
|
INO Stock Price Increased 16.44%: Why It Happened
- The stock price of Inovio Pharmaceuticals Inc (NASDAQ: INO) increased by 16.44% on Friday, January 29. This is why it happened.
- 01/30/2021
|
Why Inovio Pharmaceuticals Could Be Headed For A GameStop-Like Short Squeeze
- INO is one of the most highly shorted biotechs and among the top 25 stocks in terms of short interest listed on the NASDAQ/AMEX/NYSE. INO has recently raised funds and is planning to start a phase 3 study of the company's COVID-19 vaccine.
- 01/28/2021
|
3 Popular Robinhood Stocks That Could Be Better Than Bitcoin in 2021
- None of them outperformed the cryptocurrency in 2020, but that could change this year.
- 01/28/2021
|
7 Great Cheap Stocks To Buy For Solid Growth In 2021
- Some of the best cheap stocks for 2021 include chipmakers like UMC stock and pharmaceuticals in the COVID-19 vaccine race such as INO stock. The post 7 Great Cheap Stocks To Buy For Solid Growth In 2021 appeared first on InvestorPlace.
- 01/26/2021
|
Why Editas Medicine, Inovio, Dyne, and CytomX Stocks Are Falling Today
- All four biotechs announced the pricing of stock offerings.
- 01/21/2021
|
Inovio's stock falls after it announces public offering
- Shares of Inovio Pharmaceuticals Inc. were down 5.1% in premarket trading on Thursday, the day after the company announced a public offering of 17,700,000 shares at $8.50 per share. The stock closed Wednesday at $9.72.
- 01/21/2021
|
INOVIO Announces Pricing of Public Offering of Common Stock
- PLYMOUTH MEETING, Pa., Jan. 20, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated...
- 01/20/2021
|
INOVIO Announces Proposed Public Offering of Common Stock
- PLYMOUTH MEETING, Pa., Jan. 20, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated...
- 01/20/2021
|
Is Inovio Pharmaceuticals a Buy?
- The biotech company's COVID-19 vaccine candidate may not be near the finish line, but that doesn't mean investors should count it out just yet.
- 01/20/2021
|
Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs
- Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments.
- 01/10/2021
|
Don't Sleep on Inovio Pharmaceuticals as a Serious Vaccine Contender
- When will INO stock finally turn a corner? That's a question on some investor's minds, and recent data suggests a turnaround might be afoot.
- 01/04/2021
|
Inovio Strikes $100M Coronavirus Vaccine Licensing Deal With China's Advaccine
- Shares of Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine against the novel coronavirus, were advancing Monday. What Happened: Plymouth Meeting, Pennsylvania-based Inovio announced a collaboration and licensing agreement with China-based biotech Advaccine Biopharma to market its investigational vaccine INO-4800 in the Greater China region.
- 01/04/2021
|
Inovio to partner with Chinese biotech on COVID-19 vaccine candidate in Greater China
- Shares of Inovio Pharmaceuticals Inc. were up 4.5% in premarket trading on Monday after the company announced a licensing deal with Advaccine Biopharmaceuticals Suzhou Co. Ltd. for its COVID-19 vaccine candidate.
- 01/04/2021
|
These Were the 5 Top Genetics Stocks of 2020
- Investors in fast-moving biotechs made out like bandits.
- 12/31/2020
|
Could Inovio Pharmaceuticals Be a Millionaire-Maker Stock?
- This coronavirus vaccine drugmaker has already made many of its early investors rich, but its valuation is still dirt cheap.
- 12/30/2020
|
Why Inovio Stock Sank Today
- Analysts have very different takes on the early-stage results for the company's COVID-19 vaccine candidate.
- 12/28/2020
|
6 Biotech/Drug Stocks Up Manifold in 2020 Thanks to COVID-19
- We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.
- 12/24/2020
|
Inovio Shares Rise On Positive Data For Coronavirus Vaccine Candidate That's Stable At Room Temps
- Inovio Pharmaceuticals Inc (NASDAQ: INO) shares were trading higher Thursday after the company released positive Phase 1 data on to its COVID-19 DNA vaccine candidate. What Happened: On Wednesday, Inovio published a paper including Phase 1 data on INO-4800, which was found to have been immunogenic in all test subjects.
- 12/24/2020
|
INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine
- PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the publication of peer-reviewed Phase 1...
- 12/24/2020
|
3 Wild-Card Stocks for the New Bull Market
- These stocks could shine next year, assuming they don't stumble beforehand.
- 12/19/2020
|
Are Options Traders Betting on a Big Move in Inovio Pharmaceuticals (INO) Stock?
- Investors need to pay close attention to Inovio Pharmaceuticals (INO) stock based on the movements in the options market lately.
- 12/17/2020
|
Should Investors Buy Inovio for Its Coronavirus Vaccine?
- The biotech is trailing the leaders.
- 12/13/2020
|
These 5 Mid-Cap Healthcare Stocks Had the Best Gains in 2020
- Investors favored coronavirus vaccine work, late-stage trial victories, and genetic sequencing.
- 12/11/2020
|
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Anal Dysplasia Caused by HPV-16/18
- PLYMOUTH MEETING, Pa., Dec. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and diseases associated with HPV, today announced positive Phase 2...
- 12/09/2020
|
Inovio starts dosing participants in mid-stage COVID-19 vaccine trial
- Shares of Inovio Pharmaceuticals Inc. gained 0.6% in premarket trading on Monday after the company said it started dosing participants in a Phase 2 clinical trial for its experimental COVID-19 vaccine. Inovio plans to enroll 400 adults in the randomized, blinded, placebo-controlled study by the end of the year.
- 12/07/2020
|
Why Coronavirus Stock Inovio Pharmaceuticals Shot Higher Today
- The company taps another partner to help make its coronavirus vaccine when, and if, it's approved.
- 12/03/2020
|
Inovio Strikes Coronavirus Vaccine Manufacturing Deal With Kaneka Unit
- Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine against SARS-CoV-2, issued an update on its vaccine program Thursday, sending the stock higher. What Happened: The Plymouth, Pennsylvania-based company said it has executed an agreement with Kaneka Eurogentec, an affiliate of Japanese chemicals company Kaneka Corp., for manufacturing INO-4800 at Kaneka Eurogentec's GMP plasmid production scales.
- 12/03/2020
|
Just Say No to Inovio Pharmaceuticals Stock
- While INO stock has boasted a banner year, Inovio appears no closer to a Covid-19 vaccine than any of the other 150 contenders. The post Just Say No to Inovio Pharmaceuticals Stock appeared first on InvestorPlace.
- 12/02/2020
|
4 Pharmaceutical Stocks That Aren't Worth Their Outsized 2020 Gains
- Now that companies such as Pfizer, Moderna and AstraZeneca have emerged with viable vaccines against Covid-19, the hype around many pharmaceutical stocks is fading. Here are four stocks investors should be weary of in the weeks ahead.
- 12/01/2020
|
Is Inovio Pharmaceuticals a Buy?
- A potential coronavirus vaccine isn't the only promising pipeline candidate for this small-cap biotech.
- 12/01/2020
|
Count on the Advancement of DNA Medicine with Inovio Stock
- If you're thinking that INO stock is just a wager on a Covid-19 vaccine candidate, think again. Inovio's pipeline is robust and diverse.
- 11/30/2020
|
Why Inovio Stock Is Jumping Today
- No news was still good news for some investors.
- 11/27/2020
|
4 Biotechs Likely to Gain on Coronavirus Vaccine Efforts
- In the race to develop a coronavirus vaccine, Pfizer and its partner BioNTech have a lead, closely followed by Moderna. However, four other biotechs, NVAX, TBIO, INO and VXRT, still hold potential to gain from their vaccine development efforts.
- 11/27/2020
|
Is There Room for Latecomers to the COVID-19 Party?
- Despite multiple treatments, vaccines, and tests for COVID-19 developed by leading competitors, Sorrento's CEO Henry Ji thinks the company still has an opportunity to thrive.
- 11/21/2020
|
Why Inovio Stock Slid Today
- Investors weren't impressed enough with the biotech's positive clinical data.
- 11/20/2020
|
Is Inovio Back in the Coronavirus Vaccine Race?
- The FDA has lifted a clinical hold on the biotech's phase 2 study, boosting its prospects for the future.
- 11/20/2020
|
Inovio Gets the Go-Ahead But It's Probably Too Late
- Inovio got the go-ahead from the FDA on Nov. 16 to resume its Phase 2 clinical trial. Is INO stock worth betting on this late in the game?
- 11/20/2020
|
INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting
- PLYMOUTH MEETING, Pa., Nov. 20, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced today that data from the company's novel...
- 11/20/2020
|
Inovio: Accumulate For The HPV And Brain Cancer Therapies
- First commercial approvals could be for HPV therapies in 2022. Brain cancer (glioblastoma) data could indicate a multibillion-dollar opportunity.
- 11/19/2020
|
Inovio Pharmaceutical's FDA Plight Makes It a Highly Risky Bet
- INO stock has tumbled in the past few months. Inovio needs the FDA to bail it out by allowing the advanced trials of its vaccine to begin.
- 11/18/2020
|
Inovio Analyst: COVID-19 Competition Could Be Too Great
- Inovio Pharmaceuticals Inc (NASDAQ: INO) reported Monday the lifting of the FDA-imposed partial clinical hold on the start of the Phase 2 study of INO-4800, its DNA coronavirus vaccine candidate. The Inovio Analyst: Roth Capital Partners analyst Jonathan Aschoff downgraded Inovio from Neutral to Sell and maintained an $8 price target.
- 11/17/2020
|
The Clock Is Ticking for Inovio Stock
- The FDA recently lifted the clinical hold on Inovio's Covid-19 vaccine candidate. The result could mean huge returns for INO stock.
- 11/17/2020
|
Why Inovio Stock Plunged Today
- One analyst thinks you should sell the biotech's shares.
- 11/17/2020
|
Inovio Has Little to Show for Its Covid-19 Efforts
- Inovio Pharmaceuticals has little to show for its Covid-19 efforts. INO stock is not worth more than $2, according to one short-seller.
- 11/17/2020
|
Could Inovio Pharmaceuticals Be a Millionaire-Maker Stock?
- The popularity of coronavirus vaccine makers could blind investors to the risks of this investment.
- 11/17/2020
|
Why Inovio Pharmaceuticals Stock Is Jumping Today
- The biotech delivered good news regarding its coronavirus vaccine program.
- 11/16/2020
|
Inovio Pharma to Move Forward With COVID-19 Vaccine Candidate
- Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares soared on Monday after the company provided an update for its coronavirus vaccine candidate.
- 11/16/2020
|
FDA Lifts Partial Clinical Hold On Inovio's Phase 2 Investigational Coronavirus Vaccine Study
- Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are higher after an update issued by the company on its investigational coronavirus vaccine. What Happened: Pennsylvania-based Inovio said the FDA has issued clearance for the commencement of the Phase 2 segment of the Phase 2/3 study of its DNA vaccine candidate, codenamed INO-4800, against SARS-CoV-2.
- 11/16/2020
|
At This Point, Go Ahead and Count Inovio Pharmaceuticals Out of the Vaccine Race
- INO stock is a purely speculative bet. I don't see the company being among the few that deliver a vaccine against Covid-19.
- 11/16/2020
|
Better Coronavirus Stock: Inovio Pharmaceuticals or Regeneron?
- These companies are capitalizing on the market's interest in combating the coronavirus.
- 11/14/2020
|
Is the Options Market Predicting a Spike in Inovio (INO) Stock?
- Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.
- 11/12/2020
|
Can Inovio Benefit From All Of Its Vaccine Delays?
- Shares of Inovio (NASDAQ:INO) are trading near a six-month low. The company is being battered by delays in getting its Covid-19 vaccine candidate into Phase 2 trials.
- 11/11/2020
|
Should Inovio Be On Your Buy List As It Tackles A Coronavirus Vaccine?
- Inovio has thrown its hat into the coronavirus vaccine ring with big biopharma names like Moderna, Johnson & Johnson and Pfizer. But INO stock is volatile on its vaccine news.
- 11/11/2020
|
How to Invest in the Coronavirus Vaccine Race Right Now
- Pfizer grabbed the spotlight when it released efficacy data from its phase 3 study earlier this week. But is it too late to get in on the action?
- 11/11/2020
|
5 Reasons Chasing COVID-19 Vaccine Stocks Is a Bad Idea
- Investors are setting themselves up for disappointment.
- 11/11/2020
|
Exclusive: Editor-in-Chief Of The Lancet On Coronavirus Vaccines And The Pandemic
- Richard Horton, author of The COVID-19 Catastrophe, shares his insights about what a vaccine would mean for the world and how the globe responded to the pandemic.
- 11/11/2020
|
Here's how millennials traded stocks on the Pfizer news
- Millennials were taking profits on the travel stock rise while doubling down on the stay-at-home stocks. CNBC's Kate Rooney reports.
- 11/10/2020
|
What Really Mattered With Inovio's Q3 Update
- Hint: It wasn't the company's top and bottom lines.
- 11/10/2020
|
Inovio Pharmaceuticals, Inc. (INO) CEO J. Joseph Kim on Q3 2020 Results - Earnings Call Transcript
- Inovio Pharmaceuticals, Inc. (INO) CEO J. Joseph Kim on Q3 2020 Results - Earnings Call Transcript
- 11/09/2020
|
Recap: Inovio Pharmaceuticals Q3 Earnings
- Shares of Inovio Pharmaceuticals (NASDAQ:INO) increased 2.94% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 4.00% year over year to ($0.26), which missed the estimate of ($0.19).
- 11/09/2020
|
INOVIO Reports Third Quarter 2020 Financial Results
- PLYMOUTH MEETING, Pa., Nov. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today reported financial results for the quarter ended...
- 11/09/2020
|
Inovio Plunges To 7-Month Low On Updates From Rival COVID-19 Vaccine Developers
- Coronavirus vaccine developer Inovio Pharmaceuticals Inc (NASDAQ: INO)'s stock, which was rocked in September by the partial clinical hold imposed on the planned Phase 2/3 study of the company's DNA vaccine INO-4800, is facing further pressure Monday. What Happened: Inovio shares are reacting to announcements from rival vaccine developers Novavax, Inc. (NASDAQ: NVAX) and the Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) partnership.
- 11/09/2020
|
Why Inovio Pharmaceuticals, Novavax, and Vaxart Crashed in October
- These three pre-revenue COVID-19 vaccine stocks took a beating last month.
- 11/09/2020
|
November Is a Crucial Month for this Coronavirus Vaccine Stock
- The fate of this company's late-stage trial is now in the hands of the FDA.
- 11/08/2020
|
3 Red Flags for Inovio Pharmaceuticals' Future
- Beware the risks of investing in this small-cap COVID-19 vaccine developer.
- 11/07/2020
|
Inovio Pharmaceuticals's Earnings: A Preview
- Inovio Pharmaceuticals (NASDAQ: INO) releases its next round of earnings this Monday, November 09. Get the latest predictions in Benzinga's essential guide to the company's Q3 earnings report.
- 11/06/2020
|
Avoid These 2 Coronavirus Innovator Stocks in November
- These companies aren't about to win the coronavirus vaccine race, but their competitors probably will.
- 11/04/2020
|
Inovio Responds To Partial Clinical Hold On COVID-19 Vaccine Candidate, Expects FDA Reply This Month
- Inovio Pharmaceuticals Inc (NASDAQ: INO) responded to the FDA's questions about INO-4800 and the Cellectra vaccine delivery device in October, the company confirmed to Benzinga. Inovio Continues Phase 2/3 Trial Prep: The FDA imposed a partial clinical hold in September on the planned Phase 2/3 clinical study of INO-4800, its DNA vaccine candidate against the novel coronavirus.
- 11/03/2020
|
Avoid Taking a Bet on the Deep Correction In Inovio Stock
- Small-cap biotechs are inherently challenging. With a failed INO-4800 timeline, INO stock increasingly finds itself back in this group.
- 11/02/2020
|
These 3 Popular Stocks Are More Trick Than Treat
- Think twice before buying into these businesses.
- 10/31/2020
|
Avoid Inovio Pharmaceuticals Stock Until the FDA Greenlights Trials
- While I'd like to tell you Inovio Pharmaceuticals is a blood-in-the-streets opportunity, I can't. Avoid INO stock for now.
- 10/30/2020
|
Inovio Investors Need FDA to Write Positive Prescription for Stock Gains
- The bad news is that the FDA recently halted the Inovio trial. Think about that for a moment.
- 10/29/2020
|
Why Coronavirus Vaccine Stocks Moderna, Novavax, and Inovio Are Sinking Today
- The overall stock market sell-off is pulling all three biotech stocks down.
- 10/28/2020
|
The FDA's Questions Aren't a Deal Breaker for Inovio Stock
- INO stock is down but not out as the development of a Covid-19 vaccine is bound to have some bumps in the road. The post The FDA's Questions Aren't a Deal Breaker for Inovio Stock appeared first on InvestorPlace.
- 10/27/2020
|
Investors Betting on a Coronavirus Vaccine Better Know Who Gets First Dibs in Global Pact
- The World Health Organization is managing a global vaccine program without U.S. participation, and it could have a big impact for investors.
- 10/27/2020
|
2 Coronavirus Stocks to Avoid This Month
- Clinical trial delays and skeptical scientists spell trouble for these stocks.
- 10/24/2020
|
Could the FDA Be Ready to Crash Inovio's Hopes and Dreams?
- It's been a month since the FDA put Inovio's Covid-19 vaccine on partial clinical hold. No news is definitely not good news for INO stock.
- 10/23/2020
|
Time Is Running Out on Inovio as Other Vaccine Candidates Advance
- The FDA's latest decision has dealt a killer blow to INO stock, which was already struggling to keep up with Big Pharma in the vaccine race. The post Time Is Running Out on Inovio as Other Vaccine Candidates Advance appeared first on InvestorPlace.
- 10/22/2020
|
Investors Should Buy the Phase II/III Dip in Inovio
- INO stock is in a rough spot of late, but it is poised to bounce back from these temporary setbacks with a strong product portfolio. The post Investors Should Buy the Phase II/III Dip in Inovio appeared first on InvestorPlace.
- 10/22/2020
|
Why the FDA's Inquiry of Inovio Is More Critical Than You Think
- INO stock tumbled due to the FDA asking questions about the underlying DNA vaccine. Here's why you should be concerned.
- 10/19/2020
|
Better Coronavirus Stock: Inovio Pharmaceuticals or VBI Vaccines?
- Neither biotech is in the front of the pack in developing a COVID-19 vaccine.
- 10/18/2020
|
What You Need to Know at This Stage of the Coronavirus Vaccine Race
- Two programs may seek emergency use authorization within the next six weeks.
- 10/17/2020
|
There are seven coronavirus vaccine candidates being tested in the U.S. — here’s where they stand
- The race to develop a safe and effective COVID-19 vaccine is well under way, setting the stage to bring to market the fastest vaccine in history.
- 10/14/2020
|
Inovio Stock Is a Great Long Setup for an Overreaction Trade
- A freak-out ensued after the FDA placed a halt on Inovio's Covid-19 vaccine trials, but the price dip is a chance to buy INO stock cheaper. The post Inovio Stock Is a Great Long Setup for an Overreaction Trade appeared first on InvestorPlace.
- 10/13/2020
|
Avoid Inovio Pharmaceuticals Like the Plague
- The pharma is pursuing a Covid-19 vaccine. But INO stock is risky as the company has failed to bring a product to market for 40 years.
- 10/12/2020
|
Why Is Everyone Talking About Inovio Stock?
- This popular coronavirus vaccine developer stock is down 61% from all-time highs, and the bottom has yet to arrive.
- 10/12/2020
|
Here's Why Small-Cap ETFs Are Hitting New Highs
- Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.
- 10/07/2020
|
Inovio Pharmaceuticals Does Not Need Any More Misfortune
- INO stock is plummeting after the FDA put a hold on its INO-4800 vaccine candidate. But by the time Inovio resumes the trial, will a vaccine be needed?
- 10/07/2020
|
Is Inovio a Bad-News Buy?
- There's still a chance that the biotech could have some good news on the way.
- 10/06/2020
|
The 3 Most Expensive Stocks to Avoid During a Market Crash
- Here are the three stocks that will likely be among the hardest-hit when the next market sell-off arrives.
- 10/04/2020
|
Should You Buy Biotech or Big Pharma in the COVID-19 Vaccine Race?
- One offers massive potential for gains. The other offers security.
- 10/04/2020
|
Should Investors Give Up on Inovio Pharma Stock?
- The biotech's COVID-19 efforts just hit a roadblock.
- 10/03/2020
|
Don’t Count Out Inovio Pharmaceuticals Stock Just Yet
- INO stock is now a blood-in-the-street opportunity as Inovio is currently facing a temporary hurdle from the FDA. The post Don’t Count Out Inovio Pharmaceuticals Stock Just Yet appeared first on InvestorPlace.
- 10/02/2020
|
This Latest FDA Hold Is a Crushing Blow for Reeling Inovio Stock
- Inovio has lost the race for a novel coronavirus vaccine. And INO stock could plummet, given increasing doubts about the company as a whole.
- 10/02/2020
|
How to Decide if Inovio Is a Buy After Its 28% Correction
- Inovio Pharmaceuticals fell 28% after the FDA put a partial clinical hold on vaccine trial. Should you buy INO stock on the dip?
- 10/01/2020
|
Andrew Left Talks Inovio, Fluidigm And His 'Biggest Mistake As A Short Seller'
- Citron Research founder and activist short seller Andrew Left discussed his latest ideas during an appearance on Benzinga’s PreMarket Prep show Tuesday morning.
Left has gained notoriety over the years for successfully betting against Bausch Health Companies Inc (NYSE: BHC) (formerly Valeant Pharmaceuticals) and a number of fraudulent Chinese stocks, but has also come out positive on a number of stocks he believes are true winners.
- 09/29/2020
|
Stay Long as Inovio Pharmaceuticals Stock Is Picking Up Steam Again
- Trends come and trends go, but INO stock is coming back with a vengeance because innovation never goes out of style.
The post Stay Long as Inovio Pharmaceuticals Stock Is Picking Up Steam Again appeared first on InvestorPlace.
- 09/29/2020
|
Why Investors Should Buy Moderna Instead Of Inovio
- Why Investors Should Buy Moderna Instead Of Inovio
- 09/29/2020
|
Inovio Coronavirus Vaccine Candidate Trial Halted Due to FDA Inquiry
- The regulator has a series of questions for the biotech's testing regime for INO-4800.
- 09/28/2020
|
Inovio Pharmaceuticals News: INO Stock Slammed 28% by Pause in Covid-19 Vaccine Trial
- Inovio Pharmaceuticals (INO) news for Monday includes the pausing of its vaccine trial for the novel coronavirus sending INO stock lower.
- 09/28/2020
|
7 Risky Stocks to Buy Now for Growth and Exciting Returns
- It’s a frothy market, so why not have a bit of fun while the good times roll? These risky stocks to buy have great potential.
- 09/28/2020
|
Inovio Forced To Delay Planned Phase 2/3 Testing Of Covid-19 Vaccine; Stock Plummets
- Inovio Pharmaceuticals early Monday said the FDA had forced it to delay the start of final-phase testing on its Covid-19 vaccine candidate until some questions could be answered; INO crashed.
The post Inovio Forced To Delay Planned Phase 2/3 Testing Of Covid-19 Vaccine; Stock Plummets appeared first on Investor's Business Daily.
- 09/28/2020
|
Why Inovio Stock Is Crashing Today
- The planned phase 2/3 study of COVID-19 vaccine candidate INO-4800 just hit a major speed bump.
- 09/28/2020
|
Is the FDA’s Hold on Inovio’s COVID-19 Vaccine Study Too Much?
- Things aren’t looking up for Inovio Pharmaceuticals Inc. (NASDAQ: INO), after the U.S.
- 09/28/2020
|
Inovio Plummets After Planned Phase 2/3 Coronavirus Vaccine Study Put On Partial Clinical Hold
- Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are plummeting following an adverse development in its coronavirus vaccine program.
What Happened: The Pennsylvania-based company said the FDA has imposed a partial clinical hold on the planned Phase 2/3 trial of INO-4800 – its DNA vaccine against the novel coronavirus.
- 09/28/2020
|
Inovio Stock Still Has Real Promise Despite Faltering in Vaccine Race
- INO stock lost steam due to delays in the next stage of its vaccine trials, but there are plenty of reasons why it's still a worthwhile bet.
- 09/28/2020
|
Inovio's shares tumble 33% as COVID-19 vaccine trial is put on hold
- Shares of Inovio Pharmaceuticals Inc. were halted in premarket trading on Monday before the company said the Phase 2/3 clinical trial for its COVID-19 vaccine candidate was in a "partial clinical hold" while it answered additional questions from the Food and Drug Administration. The hold is not due to an adverse event, which is what paused the Phase 3 study for AstraZeneca
AZN,
+2.47%
AZN,
+0.25%
and the University of Oxford's experimental coronavirus vaccine.
- 09/28/2020
|
Is Inovio Worth Buying During the Market Correction?
- If you're into underdogs, you might want to add this pharmaceutical company to your portfolio.
- 09/26/2020
|
Speculate on Inovio and Covid-19 Vaccine Developers
- After bottoming at $10 earlier this month, investor interest soared in the last week for INO stock and the company's DNA medicine.
The post Speculate on Inovio and Covid-19 Vaccine Developers appeared first on InvestorPlace.
- 09/25/2020
|
Inovio Stock May Very Well Be the Long Shot Vaccine Gamble Worth Taking
- Inovio's DNA-based approach gives potential advantages to its Covid-19 vaccine candidate and adds fuel to the volatility of INO stock.
The post Inovio Stock May Very Well Be the Long Shot Vaccine Gamble Worth Taking appeared first on InvestorPlace.
- 09/24/2020
|
3 Events Behind Inovio's Volatile Ride Wednesday
- Inovio Pharmaceuticals Inc. shares were volatile Wednesday amid external developments and a presentation by CEO Joseph Kim at a health care conference.
- 09/23/2020
|
Inovio Pharmaceuticals, Inc. (INO) President & CEO Joseph Kim Presents at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Transcript
- Inovio Pharmaceuticals, Inc. (INO) President & CEO Joseph Kim Presents at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Transcript
- 09/23/2020
|
Why Inovio Pharmaceuticals Stock Is Down Today
- Short-seller Citron Research strikes again.
- 09/23/2020
|
Now Is the Perfect Time to Invest in Coronavirus Vaccine Stocks
- Today, investors are better prepared to choose potential winners.
- 09/23/2020
|
DNA Vaccine Gives Inovio Pharmaceuticals Stock a Long Shelf Life
- INO stock traders may be skeptical about Inovio's main Covid-19 vaccine candidate, but the CEO made a convincing case to stay in the trade.
The post DNA Vaccine Gives Inovio Pharmaceuticals Stock a Long Shelf Life appeared first on InvestorPlace.
- 09/22/2020
|
3 Critical Catalysts on the Way for Inovio
- With three important milestones just ahead, the biotech stock will likely soar or sink in the near future.
- 09/22/2020
|
Inovio Defies Market-Wide Weakness: What's Behind The Rally?
- Inovio Pharmaceuticals Inc (NASDAQ: INO) shares have been seeing strong momentum ever since hitting a near-term low of $8.78 on Sept. 4.
- 09/21/2020
|
Inovio Pharmaceuticals Stock Could See More Downside From $16
- After a massive 2.5x rise since the March 23 lows of this year, at the current price of around $16 per share we believe Inovio Pharmaceuticals stock has run its course, and any significant upside from these levels is unlikely. INO stock has been very volatile in trade this week, and despite.
- 09/21/2020
|
Are the Gains Over for This Early Leader in the Coronavirus Vaccine Race?
- Investors came back to the biotech's shares early this week. But will the optimism stick?
- 09/19/2020
|
The Compelling Science and the Harsh Risks Behind Inovio Pharmaceuticals
- Although vaccine plays are inherently risky, the recent robust rally in INO stock is backed by strong and compelling science.
The post The Compelling Science and the Harsh Risks Behind Inovio Pharmaceuticals appeared first on InvestorPlace.
- 09/18/2020
|
Why Inovio Stock Is Bouncing Back Today
- No news is good news for the coronavirus-focused biotech.
- 09/18/2020
|
5 Top Stock Trades for Friday: TWLO, MU, F, INO, X
- Twilio, Micron, Ford, Inovio and U.S. Steel were our top stock trades for Friday.
- 09/17/2020
|
Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Cantor 2020 Global Virtual Healthcare Conference Call Transcript
- Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Cantor 2020 Global Virtual Healthcare Conference Call Transcript
- 09/17/2020
|
Why Inovio Pharmaceuticals Is Losing Steam Today
- A noted Inovio bear weighs in on the stock's strong showing this week.
- 09/17/2020
|
At This Point, There’s No Reason to Buy (or Dump) Inovio Pharmaceuticals Stock
- Curious why INO stock jumped in recent trading? Overall optimism wasn't the only reason.
- 09/17/2020
|
Electroporation Instruments Market and Competitive Landscape & Pandemic Recovery Analysis 2020 - Technavio
- The Global Electroporation Instruments Market will grow by USD 72.67 mn during 2020-2024
- 09/17/2020
|
Why Inovio Stock Is Soaring Again Today
- Investors remain enthusiastic about comments made earlier this week by Inovio's CEO.
- 09/16/2020
|
INO Stock: Why Inovio Pharmaceuticals Is Rallying 15% Today
- Inovio Pharmaceuticals teased investors on Monday that Phase 1 results were just around the corner. INO stock is still rallying.
- 09/16/2020
|
Why Inovio Pharmaceuticals Skyrocketed on Tuesday
- Shares of coronavirus stock Inovio Pharmaceuticals (INO) surged again on Tuesday. INO was up about 18% in late-morning trading and ended the trading day up 20.4% to $13.63.
- 09/15/2020
|
Inovio CEO Talks COVID-19 Vaccine Trials; Stock Up 20%
- Shares of Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine for the novel coronavirus, are on a strong three-day run.
- 09/15/2020
|
Monoclonal Antibodies: A Good Place To Be In The Time Of Covid-19 And Stock Market Bubbles
- Monoclonal Antibodies: A Good Place To Be In The Time Of Covid-19 And Stock Market Bubbles
- 09/15/2020
|
Why Inovio Pharmaceuticals Stock Is Headed Higher Today
- Inovio's shares are on the mend today.
- 09/15/2020
|
These 3 Coronavirus Stocks Could More Than Double by the End of 2020
- Each of these biotech stocks has more than tripled year to date and could still have plenty of room to run.
- 09/15/2020
|
7 Coronavirus Vaccine Stocks to Watch as Approval Nears
- Whether or not we get an 'October Surprise' from President Donald Trump, these coronavirus vaccine stocks look hot now.
AstraZeneca (NYSE:AZN)
CureVac (NASDAQ:CVAC)
GlaxoSmithKline (NYSE:GSK)
Inovio (NASDAQ:INO)
Johnson & Johnson (NYSE:JNJ)
Moderna (NASDAQ:MRNA)
Novavax (NASDAQ:NVAX)
The post 7 Coronavirus Vaccine Stocks to Watch as Approval Nears appeared first on InvestorPlace.
- 09/14/2020
|
Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at H.C.
- Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at H.C.
- 09/14/2020
|
Coronavirus Vaccine Race: 7 Key Things You'll Want to Know
- Here are the answers to your top questions about where things stand with the development of COVID-19 vaccines.
- 09/13/2020
|
As Its Vaccine Dreams Fade, Inovio Stock Will Keep Retreating
- INO stock has pulled back some 72% from its highs. But the fade makes sense, and even at a cheaper price the stock still looks like an avoid.
- 09/10/2020
|
Inovio Analyst Says Thermo Fisher Deal 'One Solid Step' Toward COVID-19 Vaccine Commercialization
- Inovio Pharmaceuticals Inc (NASDAQ: INO), which has had a legal tussle with its South Korean CDMO, announced Tuesday an agreement with Thermo Fisher Scientific Inc.
- 09/09/2020
|
Has Inovio Stock Peaked?
- After a furious rally during the first half of the year, Inovio's stock has cooled off significantly. Can the company turn things around?
- 09/09/2020
|
Inovio Stock Is Much More Than a Coronavirus Play
- Some traders will label INO stock as nothing more than a coronavirus stock. Dig deeper and you'll see that there's much more in the pipeline.
- 09/08/2020
|
Inovio Adds Thermo Fisher As A Coronavirus Vaccine Manufacturing Partner
- Inovio signed Thermo Fisher as a manufacturer of its coronavirus vaccine candidate, but INO stock fell; company not included among nine vaccine makers pledging safety first amid pressures.
The post Inovio Adds Thermo Fisher As A Coronavirus Vaccine Manufacturing Partner appeared first on Investor's Business Daily.
- 09/08/2020
|
Shares of Inovio rise 6% on vaccine manufacturing deal with Thermo Fisher
- Shares of Inovio Pharmaceuticals Inc. INO, -2.84% gained 6.5% in premarket trading on Tuesday after the company said it had added Thermo Fisher Scientific TMO, -2.30% as a manufacturing partner for its COVID-19 vaccine candidate.
- 09/08/2020
|
How to Invest in Coronavirus Vaccine Stocks
- Just follow these three simple steps.
- 09/06/2020
|
Scott Gottlieb discusses vaccine timeline: This will be a staged authorization approval
- Moderna’s stock is down today after CEO Stephanie Bancel told CNBC the company plans to slow its enrollment of its clinical vaccine trial to ensure it has sufficient representation of minorities at risk for the disease.
- 09/04/2020
|
Got $5,000? Invest It in Any of These 6 Coronavirus Vaccine Stocks
- These businesses are backed by science, and they've already got orders lined up for their experimental vaccines.
- 09/04/2020
|
Coronavirus Vaccine Roundup, Early September
- Taking a looking at the COVID-19 vaccine development landscape across various classes, including viral vectors, genetic vaccines, recombinant protein vaccines, attenuated virus vaccines, inactivated virus vaccines, and virus-like particles.
- 09/04/2020
|
Former White House physician discusses concerns with rolling out a COVID-19 vaccine too early
- Former White House Physician Jennifer Pena speaks with Yahoo Finance's Zack Guzman about the CDC telling states to be ready to distribute a coronavirus vaccine on November 1.
- 09/03/2020
|
Inovio Stock Is a Longshot Covid-19 Bet
- Numerous well-funded coronavirus vaccines are rapidly proceeding through clinical trials. INO stock risks being left behind.
- 09/03/2020
|
3 Heavily Shorted Coronavirus Vaccine Stocks
- Short-sellers are betting against these stocks big time. But that could set up big opportunities for investors if these biotechs have positive news on the way.
- 09/03/2020
|
Why Inovio Pharmaceuticals Stock Dropped Today
- The biotech company continues to give up the gains it earned earlier this year.
- 09/02/2020
|
Inovio shares tumbled 8% after short seller Muddy Waters says don't believe the COVID-19 vaccine hype
- Inovio Pharmaceuticals Inc. shares INO, -7.88% slid 8% Wednesday, after Muddy Waters said it has taken a short position in the stock, which has been boosted this year by high hopes for its COVID-19 vaccine candidate.
- 09/02/2020
|
The Key Reasons Investors Should Avoid Inovio Pharmaceuticals Stock
- The first time I highlighted opportunity in Inovio Pharmaceuticals (NASDAQ:INO), it traded at just $4.86 a share. That was in late January.
- 09/02/2020
|
9 Reasons Why The Race For Major COVID-19 Vaccine Revenues Has Greatly Narrowed
- The huge amount of Operation Warp Speed funding for its six vaccines has helped them become somewhat dominant leaders in the race for a sizable share of the market.
- 09/02/2020
|
Better Coronavirus Stock: Inovio Pharmaceuticals or Novavax?
- One of these high-flying biotechs is set up to stand out over the long-term.
- 09/02/2020
|
Competitive Advantages Of Inovio's COVID Vaccine Makes Current Low Price A Buying Opportunity
- Inovio's COVID-19 vaccine race is not run.
- 09/01/2020
|
Why Inovio Stock Slipped Today
- The more important question is: Why have Inovio's shares fallen for several weeks now?
- 09/01/2020
|
Novavax: COVID-19 Gave It Fuel, But It's Running Near Empty
- NVAX had run over 4,000% YTD at its peak. COVID-19 vaccine hype is giving it some much-needed fuel after failing two late-stage clinical trials in 2016 and 2019.
- 08/31/2020
|
Is The Party Over for Inovio Stock? It Depends
- Nevertheless, while it's not out of the running just yet, it may be best not to take a gamble with INO stock. Sit on the sidelines for now, and wait for a more compelling entry point.
- 08/31/2020
|
FDA Head Says A COVID-19 Vaccine Could Get Emergency Approval Without Phase 3 Trial Results: FT
- The United States Food and Drug Administration is willing to expedite the COVID-19 vaccine authorization process, including granting emergency use authorization to a candidate before it completes late-stage clinical trials, according to Chairman Stephen Hahn.
- 08/31/2020
|
Has The COVID-19 Vaccine Stock Bubble Burst?
- COVID-19 vaccine stocks have gotten slammed this month.
- 08/30/2020
|
Are These the 3 Best Coronavirus Stocks to Buy Now?
- Looking at clinical trial data and other key elements offers us the answer.
- 08/29/2020
|
How Moderna Will Fare After Posting Strong Clinical Results
- Moderna posted strong clinical results that failed to lift shares. Phase 3 results will follow over the next two years.
- 08/28/2020
|
3 Reasons You Should Still Keep an Eye on Inovio Pharmaceuticals
- INO stock is dropping on news that its Covid-19 vaccine candidate is falling behind more established candidates. But science says there may still be a chance.
- 08/27/2020
|
1 Key Thing You Might Be Overlooking With Inovio
- The biotech's coronavirus vaccine candidate gets the spotlight, but you might want to shine some light on this program, too.
- 08/27/2020
|
Inovio Shares Have Been Hot in 2020 but Watch for a Volatile September
- Although Inovio shares have skyrocketed this year as part of the vaccine development efforts, the momentum in INO stock may not not be strong.
The post Inovio Shares Have Been Hot in 2020 but Watch for a Volatile September appeared first on InvestorPlace.
- 08/27/2020
|
Thinking of Buying Inovio Stock? Here's What You Need to Know
- The pharmaceutical company remains a step behind coronavirus vaccine leaders -- in funding and in the clinical trial timeline.
- 08/26/2020
|
Inovio: A Viable Short, Falling Behind The Leaders In COVID-19 Vaccine Development
- INO is up over 300% year-to-date despite the recent sell off. INO-4800 got out of the blocks quickly, but the pace of development has faded a little.
- 08/25/2020
|
Inovio Stock Is a Sideshow, Not a Serious Investment
- INO stock is putting vaccine news front and center -- in place of strong fundamentals. If you decide to take a chance, be aware -- it's a specuative on
The post Inovio Stock Is a Sideshow, Not a Serious Investment appeared first on InvestorPlace.
- 08/25/2020
|
Investing for the Election: 6 Vaccine Stocks to Buy for Operation Warp Speed
- These are the top stocks to buy based on the 2020 U.S. presidential election, with new stock picks updated daily from the sharpest investing minds in the business.
- 08/24/2020
|
6 Hot Coronavirus Stocks Moving At “Warp Speed”
- Even a vaccine that's 50% effective with some side effects would be a game changer. The Trump Administration is throwing billions into that hope and investors are seeing big profits.
- 08/24/2020
|
Why Heat Biologics, Inovio Pharmaceuticals, and Novavax Are Getting Clobbered Today
- Reports of an early approval for AstraZeneca's COVID-19 vaccine are sending these three stocks lower today.
- 08/24/2020
|
3 Coronavirus Stocks to Go on the Defensive
- The pandemic shows no signs of slowing, it's time to use any signs of weakness in coronavirus stocks as a buying opportunity.
The post 3 Coronavirus Stocks to Go on the Defensive appeared first on InvestorPlace.
- 08/24/2020
|
3 Coronavirus Stocks That Could Double by the End of 2020
- Here's exactly how they could realistically pull it off.
- 08/23/2020
|
Inovio Becomes a Covid-19 Longshot
- No one knows which of the many vaccine candidates will be safe and effective, but Inovio's unique approach has left it without a major manufacturing contract.
The post Inovio Becomes a Covid-19 Longshot appeared first on InvestorPlace.
- 08/20/2020
|
Inovio Pharmaceuticals Stock Isn’t Just a Solid Covid-19 Play
- Encouraging preliminary results for its Covid-19 vaccine and its budding HPV solutions make INO stock a great bet at this stage.
The post Inovio Pharmaceuticals Stock Isn’t Just a Solid Covid-19 Play appeared first on InvestorPlace.
- 08/20/2020
|
COVID-19: The Real Results Are A Long Way Away
- Hope for a successful vaccine by the winter is fueling trials at a record pace.
- 08/19/2020
|
Meet the Hot New Coronavirus Vaccine Stock That's Already Bigger Than Inovio and Novavax
- CureVac (NASDAQ: CVAC) held its initial public offering (IPO) on the Nasdaq stock exchange last week. CureVac expected the IPO share price would be between $14 and $16. Here's what you'll want to know about the company that's already bigger than rival coronavirus vaccine makers Inovio Pharmaceuticals (NASDAQ: INO) and Novavax (NASDAQ: NVAX).
- 08/19/2020
|
Inovio Pharmaceuticals is Still Very Relevant Despite Speculative Nature
- With more competition in the vaccine race, INO stock lost much of its sheen. But don’t rule out Inovio Pharmaceuticals because it has critical advantages that others lack.
- 08/18/2020
|
Is Inovio Pharmaceuticals a Good Coronavirus Stock to Buy?
- This stock has skyrocketed this year as part of the COVID-19 vaccine development race, but will the momentum continue?
- 08/16/2020
|
The 3 Biggest Near-Term Risks That Inovio Faces
- Inovio Pharmaceuticals (NASDAQ: INO) has enjoyed a remarkable year so far by any standard. Inovio's shares have skyrocketed close to 350%. A lot could happen to derail the company's fast track to success.
- 08/16/2020
|
Is Inovio Pharmaceuticals a Good Coronavirus Stock to Buy?
- This stock has skyrocketed this year as part of the COVID-19 vaccine development race, but will the momentum continue?
- 08/16/2020
|
The 3 Biggest Near-Term Risks That Inovio Faces
- The small biotech has some big hurdles to jump over the next few months.
- 08/16/2020
|
If You Invested $1,000 in Inovio Pharmaceuticals’s IPO, This Is How Much Money You'd Have Now
- Buying shares in this small-cap biotech hasn't made long-term investors rich -- at least, not yet.
- 08/15/2020
|
Could Inovio Pharmaceuticals Be a Millionaire-Maker Stock?
- Buy shares of a company that isn't profitable yet and doesn't even have consistent revenue. Inovio Pharmaceuticals (NASDAQ: INO) definitely fits the bill of a company that isn't generating a profit right now and doesn't have products on the market to generate a reliable revenue stream. Could Inovio be a millionaire-maker stock?
- 08/15/2020
|
Unusual Options Activity Insight: Inovio Pharmaceuticals
- On Friday, shares of Inovio Pharmaceuticals (NASDAQ: INO) saw unusual options activity. After the option alert, the stock price moved up to $15.5. * Sentiment: BEARISH * Option Type: SWEEP * Trade Type: PUT * Expiration Date: 2020-11-20 * Strike Price: $22.00 * Volume: 445 * Open Interest: 2693 Ways Options Activity is 'Unusual'One way options activity can be considered unusual is when volume is exceptionally high. The volume of options activity refers to the number of shares contracts traded for a day. Open interest describes unsettled contracts that have been traded but not closed by a counter-party. In other words, for each contract buyer, there must be a seller. A purchased contract remains open until a seller closes it, and vice versa.A contract with an expiration date in the distant future is another tell of unusual activity. Generally, additional time until a contract expires increases the potential for it to reach its strike price and grow its time value. Time value is important in this context because it represents the difference between the strike price and the value of the underlying asset.Contracts with a strike price far from the underlying price are also considered unusual because they are defined as being "out of the money". This occurs when the underlying price is under the strike price on a call option, or above the strike price on a put option. These trades are made because the underlying asset value is expected to change dramatically in the future, and the buyer or seller can take advantage of a greater profit margin.Understanding Sentiment Options are "bullish" when a call is purchased at/near ask price or a put is sold at/near bid price. Options are "bearish" when a call is sold at/near bid price or a put is bought at/near ask price.Although the activity is suggestive of these strategies, these observations are made without knowing the investor's true intentions when purchasing these options contracts. An observer cannot be sure if the bettor is playing the contract outright or if they're hedging a large underlying position in a common stock. For the latter case, the exposure a large investor has on their short position in common stock may be more meaningful than bullish options activity.Trading Options With These Strategies Unusual options activity is an advantageous strategy that may greatly reward an investor if they are highly skilled, but for the less experienced trader, it should remain as another tool to make an educated investment decision while taking other observations into account.For more information to understand options alerts, visit https://pro.benzinga.help/en/articles/1769505-how-do-i-understand-options-alertsSee more from Benzinga * Looking Into Inovio Pharmaceuticals's Return On Capital Employed * Earnings Scheduled For August 10, 2020 * Earnings Outlook for Inovio Pharmaceuticals(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/14/2020
|
Inovio: Valuation and Volatility Keep This Analyst Sidelined
- 2020 is turning out to be a tale of two halves for Inovio Pharmaceuticals (INO).The vaccine maker's valuation increased 10-fold between January and early July, backed by vigorous coronavirus tailwinds. As one of several companies taking the fight to COVID-19, investors cheered the early development of its COVID-19 DNA vaccine candidate, INO-4800.However, sentiment has soured recently, as analysts and investors have questioned whether Inovio’s offering can go the distance against its weightier rivals. Over the past month, the share price has declined by 30%.As a company with no product to sell (Inovio’s candidates are all still in development), investors’ focus was squarely on its programs’ progress, specifically INO-4800. Although the company expanded somewhat on the previously published data from INO-4800’s Phase 1 study (38 out of 38 patients in the study achieved overall immunological responses, compared to 34 out of 36 patients in the first June update), the presentation once again failed to impress, leaving more questions unanswered.Additionally, the Phase 2/3 clinical study, which was initially expected to kick off this summer, has now been pushed back to September, leaving Inovio’s COVID-19 vaccine program with even more catching up to do. The latest developments have done nothing to alter H.C. Wainwright analyst Ram Selvaraju’s thesis. The 5-star analyst stays on the sidelines with a Neutral rating and said, “We currently do not have a price target for INO shares due to market valuation and volatility. Our prior 12-month $17 price target was derived from an estimated market value of the firm at $2.44 billion, which includes a discounted cash flow based asset value of $2.54 billion for VGX-3100 (Inovio’s candidate for the treatment of HPV-related cervical pre-cancer with Phase 3 trial data expected in Q4) and INO-4800, with 80% and 30% probabilities of approval.” (To watch Selvaraju’s track record, click here)Selvaraju’s take gets the rest of the Street’s backing. Based on 2 Buys, 5 Holds and 1 Sell, Inovio has a Hold consensus rating. However, following the recent pullback, according to the $15.60 average price target, the analysts expect an 8% premium to be added over the next 12 months. (See Inovio stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
- 08/13/2020
|
Why Inovio Pharmaceuticals Stock Is Up Today
- After a rough week on the stock market for the biotech company, investors finally think the price is right.
- 08/13/2020
|
Inovio Pharmaceuticals Shares Drop, Get a Downgrade
- Inovio’s Q2 earnings and lingering questions about its INO-4800 vaccine are combining for a big drop for INOP stock.
The post Inovio Pharmaceuticals Shares Drop, Get a Downgrade appeared first on InvestorPlace.
- 08/13/2020
|
Why Inovio Pharmaceuticals Stock Is Up Today
- After a rough week on the stock market for the biotech company, investors finally think the price is right.
- 08/13/2020
|
Is Inovio Pharmaceuticals Stock a Buy?
- Negative results from clinical trials or regulatory roadblocks can send shares of these companies plunging. On the other hand, investing in the right clinical-stage biotech stock can reap life-changing returns, particularly if the company in question develops a vaccine for an infectious disease that has spread across the world and has killed thousands of people. One company that could go on to do just that is Inovio Pharmaceuticals (NASDAQ: INO).
- 08/13/2020
|
Why Pfizer's 4% Yield Is Your Best Covid-19 Vaccine Play
- I demonstrate why Pfizer is the best choice for dividend investors playing the Covid-19 vaccine theme.
- 08/13/2020
|
What's the Outlook for Inovio Pharmaceuticals Stock?
- Its experimental coronavirus vaccine has some of the best clinical data among the 167 candidates in development.
- 08/13/2020
|
Robinhood Traders Love These 2 Coronavirus Vaccine Stocks, But Should You?
- If you've been following the race to discover a coronavirus vaccine, it won't be any shock to hear that both Moderna Therapeutics (NASDAQ: MRNA) and Inovio Pharmaceuticals (NASDAQ: INO) are among the top 100 most-traded stocks on Robinhood. Between their vigorous price movements in the last five months and their consistently advancing vaccine programs, each company's market cap has ballooned to unpredictable heights far in excess of the pre-pandemic norms. While these minor quibbles might not be very convincing to Robinhood traders, if you're evaluating these two stocks for a long-term portfolio, it's critical to understand which investing metrics to monitor and why so you can make an informed decision.
- 08/13/2020
|
Is Inovio Pharmaceuticals Stock a Buy?
- Could this biotech stock be a major winner down the road?
- 08/13/2020
|
What's the Outlook for Inovio Pharmaceuticals Stock?
- Its experimental coronavirus vaccine has some of the best clinical data among the 167 candidates in development.
- 08/13/2020
|
Why Inovio Stock Is Sinking Again Today
- Shares of Inovio Pharmaceuticals (NASDAQ: INO) were sinking 12.2% lower as of 11:16 a.m. EDT on Wednesday. This marked the second consecutive day of steep declines for the stock after Inovio's Q2 update on Monday evening didn't provide as much detail about the clinical results of its COVID-19 vaccine candidate INO-4800 as analysts wanted. The core issue for Inovio is the skepticism about just how effective INO-4800 will be in protecting against the coronavirus that causes COVID-19.
- 08/12/2020
|
Looking Into Inovio Pharmaceuticals's Return On Capital Employed
- During Q2, Inovio Pharmaceuticals's (NASDAQ: INO) reported sales totaled $267.19 thousand. Despite a 15.17% in earnings, the company posted a loss of $29.06 million. Inovio Pharmaceuticals collected $1.33 million in revenue during Q1, but reported earnings showed a $25.23 million loss.What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q2, Inovio Pharmaceuticals posted an ROCE of -0.16%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on INOReturn on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.In Inovio Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q2 Earnings Insight Inovio Pharmaceuticals reported Q2 earnings per share at $-0.2/share, which did not meet analyst predictions of $-0.17/share.See more from Benzinga * Earnings Scheduled For August 10, 2020 * Earnings Outlook for Inovio Pharmaceuticals * Benzinga's Top Upgrades, Downgrades For June 29, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/12/2020
|
Why Inovio Stock Is Sinking Again Today
- Questions about its coronavirus vaccine candidate continue to weigh on the biotech stock.
- 08/12/2020
|
Inovio Still Has a Chance to Break Out in a Big Way
- Inovio did not get the government funding or pre-orders like its competitors did, so if it happens later, INO stock will respond positively
The post Inovio Still Has a Chance to Break Out in a Big Way appeared first on InvestorPlace.
More From InvestorPlace
Why Everyone Is Investing in 5G All WRONG
America’s #1 Stock Picker Reveals His Next 1,000% Winner
Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company
Radical New Battery Could Dismantle Oil Markets
- 08/12/2020
|
Why This Inovio Analyst Is Reducing Estimates For The Coronavirus Vaccine Developer
- Inovio Pharmaceuticals Inc (NASDAQ: INO) failed to inspire confidence among investors despite revealing in its second-quarter earnings report that it is on track for a September start for a Phase 2/3 clinical study of its developmental DNA coronavirus vaccine. The Inovio Analyst: Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Inovio shares and reduced the price target from $45 to $31. The Inovio Thesis: Inovio's planned Phase 3 study in at-risk volunteers with an assumed higher case rate -- although encouraging -- poses greater execution risk and mounting competition for clinical trial resources and in-market demand, given the progress made by other vaccine developers, Duncan said in a Tuesday note. (See his track record here.)Cantor is taking a conservative stance and reduced its estimate for Inovio's number of doses sold in 2022-2026, the analyst said. Given Inovio's quarter-end cash position of $372 million, there is likely to be sufficient funding into 2023, with a bevy of potential pipeline milestones, he said. The 94% responder rate for the INO-4800 vaccine in the Phase 1 study and qualitative characterization of the composition of immune responses warrant movement of the investigational vaccine into a Phase 2/3 efficacy study, Duncan said. The analyst said he expects patient enrollment in the study to occur during the summer or early fall.View more earnings on INOThe proposed Phase 2/3 study is likely to enroll health care workers, first responders and persons in other occupations that place them at higher risk of COVID-19 infection, he said. The size and the speed of the study will depend on several factors, including the viral attack rate, Duncan said. The Rest Of Inovio's Pipeline: Inovio's other upcoming catalysts include two key data readouts from the Phase 3 REVEAL-1 and REVEAL-2 clinical studies of VGX-3100 in cervical dysplasia, the analyst said.The company is also expected to release 18-month overall survival data from INO-5401/INO-9012/checkpoint inhibitor in glioblastoma multiforme and data from the Phase 2 study of MEDI-0457 in combination with durvalumab for metastatic HPV-related squamous cell carcinoma of the head and neck, according to Cantor Fitzgerald.INO Price Action: Inovio shares ended Tuesday's session down 23.01% at $14.62. Related Links:The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earning Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates Latest Ratings for INO DateFirmActionFromTo Jul 2020Maxim GroupDowngradesBuyHold Jun 2020HC Wainwright & Co.DowngradesBuyNeutral Jun 2020Cantor FitzgeraldMaintainsOverweight View More Analyst Ratings for INO View the Latest Analyst Ratings See more from Benzinga * The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings * Inovio Coronavirus Vaccine Study Shows Months Of Immunity In Primates, Sending Stock Higher(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/11/2020
|
Stock Markets Take Late-Day Hit; Inovio, Novavax Plunge on Coronavirus Vaccine Concerns
- On Wall Street, it seemed as though Tuesday would be a repeat of Monday, with strength in the Dow Jones Industrial Average (DJINDICES: ^DJI) coupled with weakness in the tech-heavy Nasdaq Composite. Shares of Novavax were down 16% Tuesday.
- 08/11/2020
|
Coronavirus Latest: Tuesday, August 11
- Both Inovio and BionNTech announced that they are making headway in their coronavirus vaccine trials, and will be able to meet deadlines toward the end of the year or a the start of 2021. Yahoo Finance’s Anjalee Khemlani breaks down the latest news about the coronavirus on The Final Round.
- 08/11/2020
|
Inovio shares tumble as analysts say COVID-19 vaccine update left more questions than answers
- Inovio Pharmaceuticals Inc. shares tumbled 22% Tuesday, a day after the company reported a wider-than-expected second-quarter loss and offered a limited...
- 08/11/2020
|
Why This Inovio Analyst Is Reducing Estimates For The Coronavirus Vaccine Developer
- Inovio Pharmaceuticals Inc (NASDAQ: INO) failed to inspire confidence among investors despite revealing in its second-quarter earnings report that it is on track for a September start for a Phase 2/3 clinical study of its developmental DNA coronavirus vaccine.
- 08/11/2020
|
Stock Markets Take Late-Day Hit; Inovio, Novavax Plunge on Coronavirus Vaccine Concerns
- What looked like another rotation day turned into something more negative.
- 08/11/2020
|
Stocks making the biggest moves midday: Simon Property Group, Casper Sleep, Shutterstock and more
- These are the stocks posting the largest moves in midday trading.
- 08/11/2020
|
Why Dynavax Technologies, Heat Biologics, and Inovio Pharmaceuticals Are Cratering Today | The Motley Fool
- Russia's surprise vaccine announcement isn't sitting well with shareholders of Dynavax, Heat Biologics, or Inovio Pharmaceuticals.
- 08/11/2020
|
Inovio Falls Sharply as Stifel Cuts Price Target
- Stifel cut its target after the company reported a much wider second quarter loss than analysts expected.
- 08/11/2020
|
Inovio Pharmaceuticals sheds 12% after earnings miss, update on its COVID-19 vaccine
|
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
- Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) * Allovir Inc (NASDAQ: ALVR) * BioLife Solutions Inc (NASDAQ: BLFS) * BioSpecifics Technologies Corp. (NASDAQ: BSTC) (reacted to second-quarter results) * CymaBay Therapeutics Inc (NASDAQ: CBAY) * Eton Pharmaceuticals Inc (NASDAQ: ETON) * Fennec Pharmaceuticals Inc (NASDAQ: FENC) * Fulgent Genetics Inc (NASDAQ: FLGT) * Harvard Bioscience, Inc. (NASDAQ: HBIO) * Inari Medical Inc (NASDAQ: NARI) * Kura Oncology Inc (NASDAQ: KURA) * Omeros Corporation (NASDAQ: OMER) (announced positive results for the study of its lead asset in COVID-19) * Pacira Biosciences Inc (NASDAQ: PCRX) * RedHill Biopharma Ltd (NASDAQ: RDHL) * Rocket Pharmaceuticals Inc (NASDAQ: RCKT) * Seres Therapeutics Inc (NASDAQ: MCRB) (reacted to positive late-stage clinical readout) * Silk Road Medical Inc (NASDAQ: SILK) * Sorrento Therapeutics Inc (NASDAQ: SRNE) * Trevena Inc (NASDAQ: TRVN) (announced FDA nod for pain drug) * Unity Biotechnology Inc (NASDAQ: UBX) * Vaxcyte Inc (NASDAQ: PCVX)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 10) * Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) (went public Friday) * Freeline Therapeutics Holdings plc ADS (NASDAQ: FRLN) (went public Friday) * Lantern Pharma Inc. (NASDAQ: LTRN) * Nkarta Inc (NASDAQ: NKTX) * Recro Pharma Inc (NASDAQ: REPH) (reacted to second-quarter results)Stocks In Focus Equillium Announces Positive Interim Data For Lead Drug, Requests Pre-IND Meeting For COVID-19 Study Equillium Inc (NASDAQ: EQ) announced positive interim data from the first two cohorts of the Phase 1b open label, dose escalation portion of the EQUATE study of itolizumab in acute graft-versus-host disease. Across the first two dose cohorts, itolizumab has been generally well-tolerated to date, and five of seven patients achieved a complete response by day 29, the company said.Additionally, Equillium said it has submitted a request to the FDA for a pre-IND meeting to review its proposal to initiate a global randomized controlled clinical trial to study itolizumab in hospitalized patients with COVID-19.The stock was trading 21.29% higher premarket Tuesday at $12.19. Clearside's IND Application Approved For Wet AMD Study Clearside Biomedical Inc (NASDAQ: CLSD) said the FDA has accepted its IND application for CLS-AX, enabling initiation of a Phase 1/2a clinical trial of CLS-AX in neovascular age-related macular degeneration patients by the end of 2020.The dose-escalation study will assess the safety and tolerability of single doses of CLS-AX administered through suprachoroidal injection following two or more prior treatments with an intravitreal anti-VEGF agent, according to the company. Separately, the company announced second-quarter results, reporting an increase in license revenue from $45,000 in 2019 to $354,000 in 2020. The net loss per share narrowed from 15 cents to 13 cents, but was wider than the 12-cent-per-share loss expected by analysts.The stock was up 7.26% at $1.92 premarket Tuesday.Innate Pharma Receives French Government Funding For COVID-19 Research Innate Pharma SA (NASDAQ: IPHA) said it has received 6.8 million euros ($8 million) in funding from the French government to support its COVID-19 R&D activities.The company said it expects the funding to help cover the development of the COVID-19 activities it began in March 2020, including the EXPLORE COVID-19 translational research study and its two Phase 2 clinical trials, FORCE and ImmunONCOVID-20.Fennec Handed Complete Response Letter For Drug To Treat Chemotherapy-Induced Ototoxicity Fennec Pharma said it received a complete response letter Monday from the FDA regarding its NDA for Pedmark, a unique formulation of sodium thiosulfate, for intravenous administration for the prevention of ototoxicity associated with cisplatin chemotherapy in pediatric patients with localized, non-metastatic solid tumors.The stock was plunging 28.42% premarket to $7.28.See also: The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earning Catalyst's Firdapse Flunks Late-Stage Study In Neuromuscular Disease Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) said the top-line results from its Phase 3 study for Firdapse in anti-MuSK antibody positive myasthenia gravis patients did not replicate the robust positive results that were observed in the 2017 proof-of-concept study. The study did not meet the primary or secondary endpoints.The company also reported second-quarter results, showing a modest increase in revenue but a decline in EPS, which beat the consensus estimate by a penny.The stock was down 11.14% at $3.79 premarket. Ligand To Buy Pfenex For Up To $516M Ligand Pharmaceuticals Inc. (NASDAQ: LGND) and Pfenex Inc (NYSE: PFNX) announced the signing of a definitive agreement for Ligand to acquire all outstanding shares of Pfenex for $12 per share in cash or $438 million in equity value on a fully diluted basis.View more earnings on IBBAdditionally, Ligand will pay $2 per share or $78 million as a contingent value right in the event a predefined regulatory milestone is achieved by Dec. 31, 2021, for a total transaction value of up to $516 million. The transaction is expected to close in the fourth quarter.In premarket trading, Pfenex shares were jumping 63.45% to $12.52.Mesoblast Slumps As FDA Raises Questions Over Stem Cell Efficacy In Graft-Versus-Host Disease Shares of stem cell therapy company Mesoblast limited (NASDAQ: MESO) moved to the downside after FDA staffers expressed doubts over the adequacy of evidence for the efficacy of the company's remestemcel-L for treating acute graft-versus-host disease in children.The comments came in a briefing document released ahead of an Adcom meeting. The FDA's Oncologic Drugs Advisory Committee is scheduled to meet Thursday to discuss the BLA submitted by the company.The stock was down 25.66% at $12.95 premarket Tuesday.Inovio To Commence Late-Stage Coronavirus Vaccine Study In September, Q2 Results Trail Estimates Inovio Pharmaceuticals Inc (NASDAQ: INO) said it looks forward to starting a Phase 2/3 coronavirus vaccine study in the U.S. in September.The company reported second-quarter revenue of $267,187 in 2020 compared to $135,673 in 2019. The loss per share widened from 30 cents to 83 cents. Analysts estimated a loss of 17 cents per share on revenue of $2.61 million.The stock was down 11.01% at $16.90 premarket Tuesday. Earnings ICU Medical Inc's (NASDAQ: ICUI) second-quarter revenue fell from $312.3 million in 2019 to $303.4 million, and adjusted EPS fell from $1.99 to $1.65. The results, however, exceeded expectations.Separately, the company announced a long-term agreement with Grifols SA - ADR ADR Class B (NASDAQ: GRFS) to distribute a full line of non-PVC/non-DEHP IV containers for 0.9% sodium chloride injections in the U.S. Omeros said its second-quarter revenue fell from $26.8 million in 2019 to $13.5 million in 2020, with the downside blamed on the postponement of cataract procedures by ASCs and hospitals due to COVID-19.The net loss per share narrowed from 61 cents to 29 cents. The revenue missed estimates and the net loss per share was wider than the consensus estimate.Separately, the company said it has commenced concurrent underwritten public offerings of $125 million shares of its common stock and $200 million in an aggregate principal amount of convertible senior notes due 2026.The stock was down 7.83% at $19.65 premarket Tuesday.Offerings PDS Biotechnology Corp (NASDAQ: PDSB) said it intends to offer shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by the company.The stock was down 20.92% at $3.10 premarket Tuesday.On The Radar PDUFA Dates The FDA's decision on label expansion for Roche Holdings AG's Basel ADR Common Stock (OTC: RHHBY) Xolair for the treatment of nasal polyps could arrive, as the company is 10 months out from the submission of the sBLA.Earnings * BioNTech SE - ADR (NASDAQ: BNTX) (before the market open) * STRATA Skin Sciences Inc (NASDAQ: SSKN) (before the market open) * Surface Oncology Inc (NASDAQ: SURF) (before the market open) * Prevail Therapeutics Inc (NASDAQ: PRVL) (before the market open) * Generation Bio Co (NASDAQ: GBIO) (before the market open) * Fulcrum Therapeutics Inc (NASDAQ: FULC) (before the market open) * Affimed NV (NASDAQ: AFMD) (before the market open) * Burning Rock Biotech Ltd (NASDAQ: BNR) (before the market open) * Gamida Cell Ltd (NASDAQ: GMDA) (before the market open) * 10X Genomics Inc (NASDAQ: TXG) (after the market close) * Agile Therapeutics Inc (NASDAQ: AGRX) (after the market close) * Aethlon Medical, Inc. (NASDAQ: AEMD) (after the market close) * T2 Biosystems Inc (NASDAQ: TTOO) (after the market close) * Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (after the market close) * DiaMedica Therapeutics Inc (NASDAQ: DMAC) (after the market close) * HTG Molecular Diagnostics Inc (NASDAQ: HTGM) (after the market close) * Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) (after the market close) * Shockwave Medical Inc (NASDAQ: SWAV) (after the market close) * RA Medical Systems Inc (NYSE: RMED) (after the market close) * Inari Medical (after the market close)Related Link: Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates See more from Benzinga * The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs * The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/11/2020
|
Stifel cuts COVID-19 vaccine developer Inovio's price target as earnings and call leave more questions than answers
- Stifel analysts cut their stock price target for Inovio Pharmaceuticals Inc. undefined to $16 from $24 on Tuesday, after the company posted a...
- 08/11/2020
|
Stifel cuts COVID-19 vaccine developer Inovio's price target as earnings and call leave more questions than answers
- Stifel analysts cut their stock price target for Inovio Pharmaceuticals Inc. to $16 from $24 on Tuesday, after the company posted a wider-than-expected second-quarter loss and revenue that fell short of estimates. Inovio is one of many companies working to develop a COVID-19 vaccine candidate. The numbers and the call "left us (again) with more questions than answers on numerous fronts," analysts led by Stephen Willey wrote in a note to clients. These include disclosure timelines for the trial of the company's COVID-19 vaccine candidate, INO-4800. The company said it expanded a 40-patient early-stage clinical trial by another 80 participants and that most patients were showing an immunological response to the vaccine, either by achieving binding antibodies, neutralizing antibodies or T cell responses. "Our hesitancy to attribute any INO-4800-related value in our model persists and our previously reduced discount rate (9%) reflected improved perception re: the likelihood of procuring third party funding," said the note. "We believe these lingering questions, coupled with an acceleration of the competitive development landscape (and difficult-to-beat immunogenicity hurdles), forces us to revisit that assumption (+250bps)." The company reported a second-quarter loss of $128.7 million, or 83 cents a share, compared with a loss of $29.4 million, or 30 cents a share, in the year-ago period. Revenue rose to about $267,000 from about $136,000 in the year-ago quarter. Analysts surveyed by FactSet had forecast a loss of 17 cents a share on revenue of $2.6 million. Shares were down 8% in premarket trade Tuesday, but have gained 475% in the year to date, while the S&P 500 has gained 4%.
- 08/11/2020
|
Why Dynavax Technologies, Heat Biologics, and Inovio Pharmaceuticals Are Cratering Today
- Russia's surprise vaccine announcement isn't sitting well with shareholders of Dynavax, Heat Biologics, or Inovio Pharmaceuticals.
- 08/11/2020
|
Inovio To Start Phase 2/3 Study Of Covid-19 Candidate In Sept.; Shares Drop 8%
- Inovio Pharmaceuticals Inc. plans to initiate Phase 2/3 study trials of INO-4800, its experimental vaccine candidate against the novel coronavirus, in September and produce at least 1 million doses this year.The company said that it is in the process of finalizing additional manufacturing partnerships in the US and in Europe to meet the target of providing 100 million doses of its DNA vaccine in 2021. Shares, however dropped 8.3% in Tuesday’s pre-market trading after declining 6.1% at the close on Monday, as investors had expected Inovio (INO) to start mid-late trials before September.INO-4800 targets the major antigen Spike protein of SARS-CoV-2 virus, which causes COVID-19 disease. Based on what Inovio called “promising” clinical data, the company states that INO-4800 is a COVID-19 vaccine candidate with a unique and highly favorable safety profile, which produces well-balanced immune responses consisting of both neutralizing antibodies and T cells.“We are very encouraged by the immune responses of our DNA vaccine candidate, INO-4800, and we look forward to beginning our planned Phase 2/3 trials in September upon FDA concurrence,” Inovio CEO Joseph Kim said. “Inovio is razor-focused on achieving additional external funding for scale-up and manufacturing of vaccine doses.”The US Department of Defense (DoD) awarded Inovio $71 million to support large-scale manufacturing of the company's proprietary Cellectra and the procurement of other devices that are used to deliver INO-4800 intradermally. The DoD also awarded Ology Bioservices $11.9 million to work with Inovio to manufacture INO-4800 DNA plasmids.Inovio added that INO-4800 Phase 1 clinical results are now undergoing peer review for publication at a top medical journal.The value of the stock has this year already ballooned 476% with the majority of analysts staying sidelined on the stock. The Hold consensus shows 5 Holds, 1 Sell and 2 Buys. (See Inovio stock analysis on TipRanks).Maxim analyst Jason McCarthy last month downgraded the stock to Hold from Buy, citing valuation following the share’s rally.McCarthy notes that although Phase 1 clinical study data of Inovio’s COVID-19 vaccine candidate has demonstrated to be "positive", he believes the stock’s stellar year-to-date performance and the potential success of INO-4800 are priced into the shares.Even as the share price spiked so fast this year, the $22 average analyst price target still indicates 16% upside potential from current levels.Related News: Pfizer Inks Deal To Manufacture Gilead’s Covid-19 Remdesivir Treatment AstraZeneca Strikes First China Manufacturing Deal For Covid-19 Candidate Novavax Rises 5% On Earnings; $2B Covid-19 Vaccine Funding More recent articles from Smarter Analyst: * Occidental Petroleum Posts $8.4 Billion Loss in 2Q Amid Oil Price Crisis * Royal Caribbean Rises In Pre-Market On Higher Demand For 2021 Cruises * Pfenex Pops 59% On Ligand $513M Buy-Out Deal; Analyst Sees 93% Upside * American Airlines Shares Lifted By Air Travel Demand Data
- 08/11/2020
|
Stifel cuts COVID-19 vaccine developer Inovio's price target as earnings and call leave more questions than answers
- Stifel analysts cut their stock price target for Inovio Pharmaceuticals Inc. INO, -6.08% to $16 from $24 on Tuesday, after the company posted a wider-than-expected second-quarter loss and revenue that fell short of estimates.
- 08/11/2020
|
Inovio Pharmaceuticals (INO) Q2 2020 Earnings Call Transcript
- INO earnings call for the period ending June 30, 2020.
- 08/11/2020
|
Inovio Coronavirus Vaccine To Enter Mid-To-Late Stage Testing In September
- Inovio Pharmaceuticals Inc (NASDAQ: INO) said during the earnings call Monday it expected its COVID-19 vaccine to enter mid-to-late stage human trials in September, Reuters reported.Coronavirus Vaccine Update: The Pennsylvania-based drugmaker had previously estimated it would begin the phase two and three trials during summer this year.Inovio said during the earnings call it was exploring partnerships beyond the United States and Europe for its vaccine candidate, and expected repetitive revenue similar to those from the flu vaccine.The company reiterated its previous estimate of producing one million doses this year and 100 million by 2021, and said it planned to obtain additional external funding to scale up the manufacturing of the vaccine. Inovio claimed the vaccine could be stored at room temperature for over a year and in normal refrigeration for up to 5 years. The pricing of the drug would be similar to those of other companies. Rival Moderna Inc's (NASDAQ: MRNA) is reportedly the steepest priced vaccine at between to per course.View more earnings on INOQ2 Earnings Miss: Inovio posted a second-quarter loss of 83 cents per share, compared with loss of 30 cents per share in the same period a year earlier. Total revenue was $267,000, compared with $136,000 for the same period in 2019.Factset analysts had predicted a loss of 17 cents per share and revenue of $2.6 million, MarketWatch reported.The company attributed the net loss to a derivatives liability, which mandates revaluation at each reporting period. Without this expense, the net loss per share would have been 20 cents, it claimed.COVID-19 Vaccine Competitors: Moderna, Johnson & Johnson (NYSE: JNJ), Pfizer Inc (NYSE: PFE) and its partner BioNTech SE (NASDAQ: BNTX) are all nearing or already conducting late-stage human trials for their COVID-19 vaccine candidates. INO Price Action: Inovio shares traded 6.8% lower at $17.70 in the after-hours session after reporting the earnings.See more from Benzinga * Facebook Forms New Group To Rationalize Payments Across Apps * Uber, Lyft Must Classify Drivers As Employees, In Compliance With California Law, Judge Rules * Jeff Bezos Turning Blind Eye Towards Unlicensed Songs On Twitch, Music Labels, Artists Allege(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/11/2020
|
Inovio to begin mid-to-late stage study of COVID-19 vaccine candidate in September
- The Plymouth Meeting, Pennsylvania-based company had previously said it would begin mid-stage human studies for the vaccine candidate, INO-4800, this summer. Inovio is in active talks with the U.S. Food and Drug Administration and awaits the agency's approval to begin Phase 2/3 study in September, a company executive said during a post-earnings conference call. Many drugmakers, including Moderna Inc, Pfizer Inc, Johnson & Johnson, Sanofi and AstraZeneca Plc, are also in various stages of developing a vaccine for COVID-19.
- 08/11/2020
|
Inovio Coronavirus Vaccine To Enter Mid-To-Late Stage Testing In September
- Inovio Pharmaceuticals Inc (NASDAQ: INO) said during the earnings call Monday it expected its COVID-19 vaccine to enter mid-to-late stage human trials in September, Reuters reported.
- 08/11/2020
|
Inovio Pharmaceuticals, Inc. (INO) CEO J.
- Inovio Pharmaceuticals, Inc. (INO) CEO J.
- 08/10/2020
|
Inovio Pharma stock fluctuates after results, vaccine update
- Inovio Pharmaceuticals Inc. shares fluctuated between slight gains and losses in the extended session Monday after the biotech company reported results that fell short of Wall Street estimates while it updated progress on its COVID-19 vaccine. Inovio shares were last up 0.6% after hours, following a 6.1% decline in the regular session to close at $18.99. For the year, shares are up 475%. The company reported a second-quarter loss of $128.7 million, or 83 cents a share, compared with a loss of $29.4 million, or 30 cents a share, in the year-ago period. Revenue rose to about $267,000 from about $136,000 in the year-ago quarter. Analysts surveyed by FactSet had forecast a loss of 17 cents a share on revenue of $2.6 million. The company said it expanded a 40-patient early-stage clinical trial by another 80 participants and that most patients were showing an immunological response to the vaccine. Inovio also said it received $71 million from the Department of Defense to support large-scale manufacturing of its Cellectra device that administered the vaccine.
- 08/10/2020
|
INOVIO Reports Second Quarter 2020 Financial Results; Provides DNA Medicines Clinical Program Mid-Year Update
- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today reported financial results for the quarter ended June 30, 2020. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update, including near-term expectations for its COVID-19 DNA vaccine development program and a mid-year clinical program update for its DNA medicines portfolio.
- 08/10/2020
|
Inovio Pharma stock fluctuates after results, vaccine update
- Inovio Pharmaceuticals Inc. INO, -6.08% shares fluctuated between slight gains and losses in the extended session Monday after the biotech company reported results that fell short of Wall Street estimates while it updated progress on its COVID-19 vaccine.
- 08/10/2020
|
T Cell Responses To Coronavirus Vaccines Are In The Interest Of National Security
- COVID-19 has weakened the US economy more than China's.
- 08/10/2020
|
INOVIO Reports Second Quarter 2020 Financial Results; Provides DNA Medicines Clinical Program Mid-Year Update
- PLYMOUTH MEETING, Pa., Aug. 10, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today reported financial results for the quarter ended.
- 08/10/2020
|
Zacks: Analysts Anticipate Inovio Pharmaceuticals Inc (NASDAQ:INO) Will Post Quarterly Sales of $2.08 Million
- Equities analysts expect that Inovio Pharmaceuticals Inc (NASDAQ:INO) will post sales of $2.08 million for the current quarter, Zacks reports. Four analysts have provided estimates for Inovio Pharmaceuticals’ earnings, with estimates ranging from $300,000.00 to $5.30 million. Inovio Pharmaceuticals posted sales of $140,000.00 during the same quarter last year, which would indicate a positive year-over-year […]
- 08/09/2020
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
- Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
- 08/09/2020
|
Is It Too Late To Buy Inovio Pharmaceuticals Stock?
- There's an easy and emphatic answer.
- 08/08/2020
|
Earnings Outlook for Inovio Pharmaceuticals
- On Monday, August 10, Inovio Pharmaceuticals (NASDAQ: INO) will release its latest earnings report. Check out Benzinga's preview to understand the implications.Earnings and Revenue Analysts covering Inovio Pharmaceuticals have modeled for quarterly EPS of $-0.17 on revenue of $2.61 million. In the same quarter last year, Inovio Pharmaceuticals announced EPS of $-0.3 on revenue of $135.67 thousand. If the company were to match the consensus estimate, earnings would be up 43.33%. Here's how the company's EPS has stacked up against analyst estimates in the past:Quarter Q1 2020 Q4 2020 Q3 2019 Q2 2019 EPS Estimate -0.22 -0.24 -0.26 -0.27 EPS Actual -0.26 -0.38 -0.25 -0.30 Revenue Estimate 1.91 M 2.32 M 3.93 M 5.66 M Revenue Actual 1.33 M 279.00 K 866.86 K 135.67 K Stock Performance For a full 12 months, the return has risen by 756.04%. Given that these returns are generally positive, long-term shareholders are probably relaxed going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.View more earnings on INODon't be surprised to see the stock move on comments made during its conference call. Inovio Pharmaceuticals is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://www.webcaster4.com/Webcast/Page/2021/36286See more from Benzinga * Benzinga's Top Upgrades, Downgrades For June 29, 2020 * Stocks That Hit 52-Week Highs On Friday * Benzinga's Top Upgrades, Downgrades For June 26, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/07/2020
|
Earnings Outlook for Inovio Pharmaceuticals
- On Monday, August 10, Inovio Pharmaceuticals (NASDAQ: INO) will release its latest earnings report.
- 08/07/2020
|
Hahn: FDA won’t make regulatory decisions based on preprints or news releases
- The COVID-19 pandemic has upended the long standing model for publishing clinical data as researchers and drugmakers race to share the latest findings about...
- 08/06/2020
|
Why Inovio Fell 27.9% in July
- Lack of detail in a clinical trial report weighed on the shares.
- 08/06/2020
|
It’s Time to Get Serious About Inovio Pharmaceuticals
- Due to the government's desire to develop multiple vaccine candidates and several intriguing catalysts, INO stock deserves serious consideration.
The post It’s Time to Get Serious About Inovio Pharmaceuticals appeared first on InvestorPlace.
- 08/06/2020
|
Why Hasn't Inovio Won a Huge Coronavirus Vaccine Deal from Washington Yet?
- There are several reasons why the U.S. government might be choosing not to back the development of INO-4800 with big money, but two stand out.
- 08/06/2020
|
What the Charts Say for Inovio Stock Right Now
- Inovio stock will live and die by its coronavirus vaccine results. However, INO stock continues to trade well, with a solid chart setup.
- 08/06/2020
|
Hold Off Buying The Dip in Pandemic Play Inovio Stock
- So, what's the verdict? Stay on the sidelines with INO stock for now, but consider shares if they continue falling back to lower prices.
- 08/06/2020
|
9 Stocks to Buy This Week as the Coronavirus Worsens
- With the pandemic rearing its ugly head again, these nine companies should give you significant growth potential.
- 08/06/2020
|
Global Therapeutic Vaccines Market 2020-2024: Anticipated to Grow by $3.78 Billion, at a CAGR of 43% - ResearchAndMarkets.com
|
Wednesday’s Highlights at Noon: Coca-Cola Bottling Co Consolidated (COKE), Energizer Holdings (ENR), Freeport-McMoRan (FCX), Plains All American (PAA), Inovio Pharmaceuticals (INO) - Markets
- So far Wednesday, August 5, NASDAQ is up 1.65% and the S&P is up 0.59%. Here are this morning’s most
- 08/05/2020
|
3 Most Popular Coronavirus Stocks on Robinhood: Are They Buys?
- Robinhood investors like two fast-growing biotechs and one big pharma company that each have promising COVID-19 vaccine candidates.
- 08/05/2020
|
It’s Warp Speed Ahead Now for Inovio
- Inclusion in a government program to fight the spread of the coronavirus is a major catalyst event for INO stock.
The post It’s Warp Speed Ahead Now for Inovio appeared first on InvestorPlace.
- 08/05/2020
|
Phase 3 Trials And More: Any COVID-19 Data Is Good Data, Even If It's Bad
- MRNA, PFE/BNTX, and AZN are leading the three vaccines in clinical phase 3 trials.
- 08/04/2020
|
Better Coronavirus Stock: Inovio Pharmaceuticals or VBI Vaccines?
- Inovio Pharmaceuticals (NASDAQ: INO) is enjoying its best stock performance in seven years thanks to investors' interest in its novel coronavirus vaccine program. VBI Vaccines (NASDAQ: VBIV) appears to be on track for its best year ever -- for the same reason. There are currently 25 COVID-19 vaccine candidates in clinical testing across the world.
- 08/04/2020
|
Inovio Pharmaceuticals: A Focus On The HPV Pipeline Candidates
- Inovio Pharmaceuticals: A Focus On The HPV Pipeline Candidates
- 08/02/2020
|
Better Coronavirus Stock: Pfizer or Inovio Pharmaceuticals?
- There are no signs the coronavirus pandemic is slowing down in the U.S., with more than 1,100 Americans dying every day from COVID-19 in recent days. Beyond the staggering fatalities, one estimate by the Australian National University puts the virus' potential global economic damage at over $21 trillion. The need for a coronavirus vaccine has thus become paramount to saving lives and mitigating economic catastrophes.
- 08/02/2020
|
Better Coronavirus Stock: Pfizer or Inovio Pharmaceuticals?
- Which of these cutting-edge biotech companies is leading the coronavirus vaccine race?
- 08/02/2020
|
Should You Sell These Coronavirus Vaccine Stocks?
- The shares have soared as vaccine candidates progress through human trials. Can the gains continue?
- 08/02/2020
|
Inovio Pharmaceuticals: COVID-19 Vaccine Not the Only Path to Success
- After a market crushing performance during the first half of the year, one of 2020’s best performers has been struggling of late. The last month has seen shares of Inovio Pharmaceuticals (INO) decline by 27%. The publication of murky data for the biotech’s COVID-19 DNA vaccine candidate INO-4800 and a sense it is lagging behind competitors’ progress have raised concerns amongst investors. Add in an overheated valuation and maybe a sell off was inevitable.As a reminder, despite the souring sentiment, the stock is still up by a majestic 510% on a year-to-date basis.With the public and investors’ focus squarely on COVID-19 related developments, it is easy to forget these companies have other drugs in various states of development.On Thursday, Inovio shares broke out of the downtrend and surged by 9%. For a change the uptick had nothing to do with COVID-19.Which brings us to INO-3107, Inovio’s treatment for recurrent respiratory papillomatosis (RRP). Inovio announced INO-3107 had been designated Orphan Drug status by the FDA. The status is given to rare diseases with a small addressable market that otherwise not be profitable enough to develop, therefore the government steps in to provide support. The designation should provide Inovio with various incentives, including seven years of market exclusivity should the treatment gain FDA approval, a prescription drug user fee waiver, and tax credits for qualified clinical trials.INO-3107 is currently being evaluated in a Phase 1/2 trial with 63 subjects participating in the study. Defined by the growth of noncancerous tumors that can result in life-threatening airway obstructions, there are currently 15,000 RRP cases in the U.S.H.C.Wainwright analyst Ram Selvaraju commented, "These incentives could help the company advance future clinical development of INO-3107 and maximize the DNA medicine’s commercial value, in our view… We believe INO-3107 has the potential to address the underlying recurring virus, delay or eliminate the need for frequent surgery, and provide a long term treatment option to improve the quality of life for both adult and pediatric RRP patients.”However, it is still early days in the drug’s development and for now Selvaraju stays on the sidelines with a Neutral rating. (To watch Selvaraju’s track record, click here)Selvaraju’s colleagues agree. Inovio currently has a Hold consensus rating, based on 2 Buys, 5 holds and 1 Sell. The average price target comes in at $22 and implies shares will remain range bound for now. (See Inovio stock-price forecast on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 07/31/2020
|
3 Reasons to Sell Inovio Stock
- Inovio has made advances towards developing a coronavirus vaccine. However, now isn't the time to invest in INO stock.
- 07/31/2020
|
Why The Coronavirus Pandemic Could Influence Biotech Stocks For Years To Come
- Covid-19 could drive biotech stocks for years to come, experts say, as investors try to pinpoint the next big winner to churn out a vaccine or treatment.
The post Why The Coronavirus Pandemic Could Influence Biotech Stocks For Years To Come appeared first on Investor's Business Daily.
- 07/30/2020
|
Inovio Coronavirus Vaccine Study Shows Months Of Immunity In Primates, Sending Stock Higher
- Inovio Pharmaceuticals Inc (NASDAQ: INO) shares were moving to the upside Thursday after slipping 6.3% in the prior session.
- 07/30/2020
|
Inovio Coronavirus Vaccine Study Shows Months Of Immunity In Primates, Sending Stock Higher
- Inovio Pharmaceuticals Inc (NASDAQ: INO) shares were moving to the upside Thursday after slipping 6.3% in the prior session.
What Happened: Plymouth, Pennsylvania-based...
- 07/30/2020
|
Wednesday’s Midday Movers: Celldex (CLDX), Cameco (CCJ), TG Therapeutics (TGTX), Dynavax (DVAX), Inovio Pharmaceuticals (INO) - Markets
- So far Wednesday, July 29, NASDAQ is up 1.03% and the S&P is up 1.94%. Let’s take a look at
- 07/29/2020
|
Inovio's Drug For Rare Respiratory Tract Disorder Granted Orphan Designation
- Inovio Pharmaceuticals Inc (NASDAQ: INO) shares were volatile Wednesday after the company announced Orphan Drug Designation for one of its pipeline drugs.
- 07/29/2020
|
Got $10,000? Invest in These 3 Coronavirus Vaccine Stocks
- These three stocks are exposed to big upsides from vaccine development, but they're also rich with research collaborations and government funding.
- 07/29/2020
|
Whatever Happens to Inovio Pharmaceuticals, Insiders Will Do Just Fine
- Inovio Pharmaceuticals' (NASDAQ:INO) insiders are benefitting from the novel coronavirus and the rise of INO stock.
The post Whatever Happens to Inovio Pharmaceuticals, Insiders Will Do Just Fine appeared first on InvestorPlace.
- 07/29/2020
|
INOVIO Receives Orphan Drug Designation From U.S. FDA for DNA Medicine INO-3107 To Treat Rare Disease Recurrent Respiratory Papillomatosis (RRP)
- PLYMOUTH MEETING, Pa., July 29, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) today announced that the U.S.
- 07/29/2020
|
Biotech Bonanza - Second Half Outlook
- Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest creates an ideal environment for biotechs to continue outperforming the market.
- 07/28/2020
|
Better Coronavirus Stock: Inovio vs. Vaxart
- Two biotechs with promising COVID-19 vaccine candidates. But one is the clear winner right now.
- 07/28/2020
|
Monday's Midday Stock Update: Sierra Wireless (SWIR), Inovio Pharmaceuticals (INO), Aerie Pharma (AERI), Opko Health (OPK), MGM Resorts (MGM) - Markets
- So far Monday, July 27, NASDAQ is up 2.28% and the S&P is up 0.89%. Here are this morning’s most
- 07/27/2020
|
Inovio Is Too Risky for the Average Investor
- With the likelihood of a coronavirus vaccine still largely unknown, betting on INO stock based on its vaccine candidate is too risky.
The post Inovio Is Too Risky for the Average Investor appeared first on InvestorPlace.
- 07/27/2020
|
Here's Your Guide to the Coronavirus Vaccine Leaders
- Let's take a look at what's happened so far and what's on the horizon.
- 07/26/2020
|
Should Inovio Pharmaceuticals Be Your Next Coronavirus Buy?
- Inovio is making headlines with its coronavirus vaccine candidate. Investors have been reaping the rewards.
- 07/25/2020
|
Why Moderna, Vaxart, Inovio, and BioNTech Stocks Dropped Today
- COVID-19 vaccines might not be the moneymakers investors are hoping for.
- 07/24/2020
|
The Further It Lags in the Vaccine Race, the Riskier Inovio Stock Looks
- Inovio Pharmaceuticals (NASDAQ:INO) is a contender in the hyper-competitive field to develop a novel coronavirus vaccine, but with the company falling behind rivals, INO stock is risky. Source: Ascannio / Shutterstock.com INO stock is up a staggering 719.70% this year, as of July 22.
- 07/24/2020
|
Cramer: Here are stocks that stand out in crowded race for a coronavirus vaccine
- CNBC's Jim Cramer said Thursday that Johnson & Johnson has the most promising stock of the companies that are developing a vaccine to prevent Covid-19.
- 07/23/2020
|
History and Competition Suggest Caution Toward Inovio Stock
- INO stock has rallied more than 700% so far this year. But the company needs to succeed where it has failed in the past and beat rivals in the process.
- 07/23/2020
|
9 Stocks to Buy This Week as the Coronavirus Worsens
- With the pandemic rearing its ugly head again, these nine companies should give you significant growth potential.
- 07/22/2020
|
9 Stocks to Buy for the Second Coronavirus Wave
- With rising coronavirus hospitalizations dominating headlines, investors will shift back toward a pandemic mentality. Here are nine stocks to buy this week to capitalize on this trend.
- 07/22/2020
|
Kamada: Under-The-Radar COVID-19 Therapy Play With Downside Protection And Margin Of Safety
- US and global pharma companies that are working on credible COVID-19 treatments are up massively YTD, often more than 100% and far surpassing performance of general pharma indices.
- 07/22/2020
|
4 Catalysts Could Drive Inovio Pharmaceuticals Stock to Near-term Highs
- Inovio Pharmaceuticals remains one of the most undervalued of the vaccine makers. Even after a 455% run higher, INO stock has plenty of upside fueled by plenty of catalysts.
- 07/22/2020
|
The Curtain Is Coming Down on Inovio Pharmaceuticals’ Vaccine Candidate
- As multiple companies advance vaccine candidates into late-stage clinical trials, INO stock is losing momentum. Is this the end or just a pause?
- 07/22/2020
|
4 Catalysts Could Drive Inovio Pharmaceuticals Stock to Near-term Highs
- Inovio Pharmaceuticals remains one of the most undervalued of the vaccine makers. Even after a 455% run higher, INO stock has plenty of upside fueled by plenty of catalysts.
- 07/22/2020
|
2020 Insights into the Cancer Vaccines Market - Pipeline Analysis Report - ResearchAndMarkets.com
|
Democratic lawmakers signal concern about coronavirus vaccine pricing, speed of development
- Lawmakers peppered pharmaceutical executives with questions about how COVID-19 vaccines will be manufactured, priced and distributed, the day after promising...
- 07/21/2020
|
Investors cheer as two coronavirus vaccine candidates report T-cell responses, but findings are still early stage
- At least two experimental COVID-19 vaccines produced a T-cell response in participants in early-stage clinical trials, which may indicate a more durable form...
- 07/21/2020
|
Inovio May Be Losing the Covid-19 Vaccine Race
- Moderna and AstraZeneca both are making rapid progress on their coronavirus vaccines. For Inovio, this means that the clock is ticking down.
- 07/20/2020
|
Inovio May Be Losing the Covid-19 Vaccine Race
- Moderna and AstraZeneca both are making rapid progress on their coronavirus vaccines. For Inovio, this means that the clock is ticking down.
- 07/20/2020
|
IBio's stock soars, but Novavax and Inovio stocks fall amid news on other COVID-19 vaccine candidates
- Shares of companies with COVID-19 vaccine candidates were mixed in volatile trading Monday, after the promising results from trials of vaccine candidates...
- 07/20/2020
|
Inovio Pharmaceuticals (INO) Receives a Hold from H.C. Wainwright - Markets
- In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals (INO – Research
- 07/20/2020
|
IBio's stock soars, but Novavax and Inovio stocks fall amid news on other COVID-19 vaccine candidates
- Shares of companies with COVID-19 vaccine candidates were mixed in volatile trading Monday, after the promising results from trials of vaccine candidates from Pfizer Inc.
- 07/20/2020
|
‘A Powerful Force’: Tesla’s Momentum Leads Stock-Market Surge
- Some momentum stocks, like Tesla, have yet to record a full-year profit, but their future potential and recent stock performance have still attracted hordes of buyers.
- 07/19/2020
|
Sunday’s Highlights at Noon: Dynavax (DVAX), Celldex (CLDX), Novavax (NVAX), Intuitive Surgical (ISRG), Inovio Pharmaceuticals (INO) - Markets
- So far Sunday, July 19, NASDAQ is down -1.01% and the S&P is down -0.16%. Let’s take a look at
- 07/19/2020
|
Here Are All the COVID-19 Vaccines Currently in Clinical Testing
- Leaders and laggards in the COVID-19 vaccine race -- and how likely they are to win approval.
- 07/19/2020
|
Saturday’s Midday Movers: Dynavax (DVAX), Celldex (CLDX), Novavax (NVAX), Intuitive Surgical (ISRG), Inovio Pharmaceuticals (INO) - Markets
- So far Saturday, July 18, NASDAQ is down -1.01% and the S&P is down -0.16%. Let’s take a look at
- 07/18/2020
|
Stocks To Watch: Vaccine Players, Earnings Blitz And Fiscal Debate
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 07/18/2020
|
Which Biotech Company Has the Most Promising Coronavirus Vaccine?
- A coronavirus vaccine has the potential to not only save countless lives, but also to mitigate trillions in economic damage.
- 07/18/2020
|
Coronavirus Vaccine Developers Rise After Fauci's Comments
- America's highest-profile medical professional waxes optimistic on the potential for a "safe and effective" vaccine by 2021.
- 07/17/2020
|
5 Stock Gainers for Friday: Inovio, Moderna, Novavax
- U.S. stocks were wavering Friday in the face of slumping U.S. consumer sentiment and escalating rates of coronavirus infections. Consumer sentiment last month missed economists' forecasts, falling to 73.2 from 78.1 in June, according to the University of Michigan. Coronavirus cases in the U.S. have risen to nearly 3.6 million, with deaths at 138,543, according to Johns Hopkins University.
- 07/17/2020
|
3 Game-Changing Coronavirus Vaccine Stocks That May Make You Rich
- Investors need a bevy of high-growth stocks as part of every well-rounded biotech portfolio, and the market's furor surrounding the prospect of a COVID-19 vaccine creates the perfect conditions for those seeking returns in the biotech space. Thanks to the market's excitement about the vaccine development activities of these three companies, each has exhibited stunning growth in the first half of this year, making them attractive options for investors seeking profit. Before the pandemic, Inovio Pharmaceuticals (NASDAQ: INO) was a typical biotech stock, with its growth dependent entirely on favorable clinical trial outcomes.
- 07/17/2020
|
4 Debt-Free Companies With Strong Stocks to Buy
- Debt-free and in the limelight, strong fundamentals mean these companies have ample financial headroom for aggressive growth.
The post 4 Debt-Free Companies With Strong Stocks to Buy appeared first on InvestorPlace.
- 07/17/2020
|
Better Coronavirus Stock: Inovio vs. Sorrento Therapeutics
- It's a great time to be a small biotech focused on fighting COVID-19. Inovio Pharmaceuticals (NASDAQ: INO) stock has skyrocketed more than 600% higher so far this year. Shares of Sorrento Therapeutics (NASDAQ: SRNE) have more than doubled.
- 07/17/2020
|
3 Game-Changing Coronavirus Vaccine Stocks That May Make You Rich
- These three vaccine stocks show no signs of slowing down their breathtaking pace of growth.
- 07/17/2020
|
Better Coronavirus Stock: Inovio vs. Sorrento Therapeutics
- These high-flying biotechs have high hopes for their COVID-19 programs.
- 07/17/2020
|
Manila May Return to Lockdown; Fauci Has Warning: Virus Update
- (Bloomberg) -- Manila, capital of the Philippines, may return to a lockdown as coronavirus cases rise while Jakarta in Indonesia keeps social-distancing measures set to expire amid a surge in cases. Australia’s most-populous state will tighten restrictions on gatherings and venues.Florida and Texas reported record numbers of virus deaths. Brazil surpassed 2 million cases as the virus spreads in the country’s poorer, remote areas.Dr. Anthony Fauci said many states reopened too quickly and called for “a time out” yet said he expects results for a clinical trial on monoclonal antibodies by late summer or early fall. The U.K. accused Russian state intelligence of trying to steal vaccine research.Key Developments:Global Tracker: Cases top 13.7 million; deaths near 588,000New lockdowns are threatened in virus-stricken U.S. statesChildhood Covid-19 infections mount with schools eyeing openingsCovid cold war flares up with claims of Russian vaccine attackNew York launches national ad campaign to promote mask wearingSubscribe to a daily update on the virus from Bloomberg’s Prognosis team here. Click VRUS on the terminal for news and data on the coronavirus.South Korea Confirms 60 More Cases for 13,672 Total (9:40 a.m. HK)South Korea reported 60 more coronavirus cases in 24 hours, raising the total tally to 13,672, according to data from the Korea Centers for Disease Control & Prevention.Two additional deaths were reported for a total of 293. Of the additional cases, 21 are locally infected, while 39 are imported cases, according to the report.Australia’s Most-Populous State Tightens Restrictions (9:36 a.m. HK)Australia’s most-populous state -- New South Wales -- will further tighten restrictions for gatherings and venues, including clubs and cafes, Premier Gladys Berejikliantells told reporters.Meanwhile, Australia’s Victoria state recorded an additional three coronavirus deaths and posted its biggest ever increase in cases -- with 428 overnight.Starting from Friday of next week, restrictions already imposed in New South Wales on pubs that include limiting bookings to a maximum of 10 people, will be extended to clubs, cafes and all indoor hospitality venues, she said.Weddings and functions can have a maximum of 150 guests, and all must be seated and “no dancing, no singing, no mingling,” she said. Funerals and places of worship are restricted to 100 people.Jakarta Keeps Loose Social Distancing Measures as Cases Surge (9:08 a.m. HK)Indonesia’s capital will remain under social-distancing measures for two more weeks after new coronavirus cases surged since the easing of a partial lockdown a month ago.The transition period to completely exit a so-called large scale social distancing rules to contain the virus will be extended to July 30, Governor Anies Baswedan said in a message posted on YouTube. The city, which last month allowed offices, places of worship, restaurants and shopping malls to reopen in phases with some limits, was set to lift the remaining restrictions on Friday.Jakarta, home to more than 10 million people, has remained one of Indonesia’s virus hotspots with the gradual easing of social distancing rules allowing most economic activities to resume, fueling a surge in infections. The continuation of curbs may hit a nascent recovery in Southeast Asia’s largest economy.Meadows Calls Fauci’s 1918 Flu Comparison ‘Irresponsible’ (9:00 a.m. HK)President Donald Trump’s chief of staff criticized Anthony Fauci for comparing the current coronavirus outbreak to the 1918 flu pandemic, calling it “irresponsible,” after reprimanding another top White House adviser for publicly attacking Fauci, the nation’s top infectious disease expert.“He suggested that this virus was worse than, or as bad as, the 1918 flu epidemic,” Mark Meadows said during a Fox News interview. “I can tell you that not only is that false, it’s irresponsible to suggest so.”Fauci said earlier this week at an event sponsored by Georgetown University that the coronavirus is a “pandemic of historic proportions” and “when history looks back on it, will be comparable to what we saw in 1918,” when influenza killed tens of millions of people worldwide.Manila May Return to Lockdown as Infections Rise (8:58 a.m. Hong Kong)The Philippine capital will remain under loose movement restrictions starting July 16, but may return to lockdown in two weeks if coronavirus cases continue to rise.Metro Manila will stay under general community quarantine until the end of July, allowing most businesses to remain open, presidential spokesman Harry Roquesaid at a televised briefing. The health department on Thursday said the nation added 2,498 cases, bringing total infections to 61,266 while deaths rose by 29 to 1,643.Coronavirus cases in the Philippines have more than tripled since stay-home orders in the capital were lifted and most businesses were allowed to reopen starting June. The Philippines has the second-highest number of infections in Southeast Asia, next to Indonesia.Japan Suspends Bids for Program to Support Restaurants: Jiji (7:54 a.m. HK)Japan’s agriculture ministry has decided to suspend bids seeking contractors for its “Go To Eat” campaign aimed at supporting eating establishments hit by the coronavirus outbreak, Jiji reports without attribution.“It would make a bad impression if bids were started under the current circumstances,” Jiji quotes an unidentified government official as saying.A separate “Go To” travel campaign to help ailing tourism industry came under fire out of concerns it would fuel the spread of infections. Japan’s government decided to exclude Tokyo, where infections are again surging, from the nationwide program.Netflix Warns on U.S. Locations (6:20 a.m. HK)Netflix Inc. said that while the company has resumed making shows in Asia and Europe, “current infection trends create more uncertainty for our productions in the U.S.” Other parts of the world such as India and some of Latin America “are also more challenging and we are hoping to restart later in the year in these regions,” Netflix said in a shareholder letter.The company warned that “growth is slowing as consumers get through the initial shock of Covid and social restrictions.” Netflix shares plunged after its subscriber forecast missed estimates.Fauci Calls for ‘Time Out’ on Reopening (5:54 p.m. NY)Anthony Fauci said many states rushed too quickly to reopen without bringing the virus adequately under control, leading to the resurgence in states across the U.S. south and west.“We’ve got to regroup, call a time out,” Fauci, director of the National Institute for Allergy and Infectious Disease, said live in an interview with Facebook Inc. Chief Executive Officer Mark Zuckerberg.Fauci also told Zuckerberg that he expects results for a clinical trial on monoclonal antibodies by late summer or early fall.“What we really need are drugs that, when given early, can prevent a symptomatic person from requiring hospitalization or very dramatically diminish the time that they’re symptomatic,” Fauci said during the Facebook Live interview on Thursday. Monoclonal antibodies can be administrated intravenously or through a shot.Washington State Pauses Reopening (5:50 p.m. NY)Washington State Governor Jay Inslee further curbed the state’s reopening, limiting social gatherings to 10 people in counties returning to normal business because of the rise in virus cases.“Unless something changes we will have to make more decisions that are difficult,” Inslee, a Democrat, told reporters. “So we hope everyone bears down right now.”On Tuesday, Inslee paused any new reopening for at least two weeks. The limits on social gatherings do not apply to weddings, funerals or religious services. The state’s department of health reports 43,046 cases and 1,421 deaths.Brazil Tops 2 Million Cases (5:35 p.m. NY)Latin America’s biggest economy reported 45,403 new cases of Covid-19 in a 24-hour period, pushing the number of infections to more than 2 million. The death toll rose by 1,322 to 76,688. Brazil trails only the U.S. on both counts.Brazil has added 1 million cases in less than a month in a rapidly shifting outbreak. Wile official numbers have stabilized in places such as Sao Paulo, the richest state, the disease is spreading fast elsewhere. The World Health Organization has said that Brazil’s outbreak may not peak until August.Texas Reports Record Deaths, Soaring Infections (5:07 p.m. NY)Texas posted its worst day of Covid-19 fatalities and recorded more than 10,000 new cases for a third straight day. The death toll rose by 129, breaking the record of 110 set on Wednesday, according to state health department data.The tally of new cases is closing in on the 300,000 mark. Governor Greg Abbott warned delegates at the state Republican convention that the worsening outbreak is leaving him with few options aside from shutting down the second-most populous U.S. state.Officials across Texas are mobilizing overflow mortuary space as communities anticipate a surge in coronavirus deaths following Fourth of July festivities. The U.S. South and Southwest are contending with explosive outbreaks after relaxing controls.U.S. Infections Rise 2.1% (4 p.m. NY)Coronavirus cases in the U.S. increased 2.1% as compared with the same time Wednesday to 3.54 million, according to data collected by Johns Hopkins University and Bloomberg News. The percentage gain was in line with the past’s week’s average of 2%. Deaths rose 0.7% to 137,897.Florida posted a record 156 new deaths, pushing the total to 4,677. Cases rose 4.6% to 315,775, compared with an average increase of 4.4% in the previous seven days.Arizona reported 3,259 new cases, a 2.5% increase to 134,613 that was below the prior seven-day average of 2.8%. The state reported 58 new virus deaths, bringing the total to 2,492.Oklahoma cases rose 7.
- 07/17/2020
|
In The Search For A COVID Cure, Biopharma ETFs May Keep Your Portfolio Healthy
- Stocks Analysis by Investing.com (Tezcan Gecgil/Investing.com) covering: Vertex Pharmaceuticals Inc, Gilead Sciences Inc, iShares Nasdaq Biotechnology ETF, Amgen Inc. Read Investing.com (Tezcan Gecgil/Investing.com)'s latest article on Investing.com
- 07/17/2020
|
Should Inovio's Lawsuits Worry Investors?
- Inovio Pharmaceuticals (NASDAQ: INO) has been around for nearly 40 years. The pandemic turned out to be a huge catalyst for Inovio, however, after the biotech began developing a vaccine candidate for potential immunization against SARS-CoV-2, the novel coronavirus that causes COVID-19. In particular, the biotech now faces high-profile legal disputes.
- 07/16/2020
|
It Looks Like Inovio Stock May Still Be Set up for an Explosive Rally
- Inovio has been on fire, and while its catalyst is tied to the coronavirus, the charts remain bullish. Let's look more closely at INO stock.
- 07/16/2020
|
Should Inovio's Lawsuits Worry Investors?
- The biotech's lawyers have become very busy in recent months.
- 07/16/2020
|
Moderna Vaccine Data Spurs Stock Market Rally
- The now familiar group of reopening stocks – cruises, energy, hotels, airlines, retail etc. – are surging on vaccine hopes.
- 07/15/2020
|
Moderna’s stock extends rally as experts await details of the coming Phase 3 study of the coronavirus vaccine candidate
- Shares of Moderna Inc. rallied 10% in trading on Wednesday morning, the day after the drugmaker shared that its COVID-19 vaccine candidate produced...
- 07/15/2020
|
Why Several Coronavirus Vaccine Stocks Not Named Moderna Fell Today
- Good news for Moderna was bad news for several of its rivals.
- 07/15/2020
|
Nasdaq Rises on Moderna Coronavirus Vaccine Hopes -- at Inovio's Expense
- The stock market moved higher Wednesday morning on optimism about a potential solution to the COVID-19 pandemic.
- 07/15/2020
|
Should Inovio Be On Your Buy List As It Tackles A Coronavirus Vaccine?
- Inovio has thrown its hat into the coronavirus vaccine ring with big biopharma names like Moderna, Johnson & Johnson and Pfizer. But INO stock is volatile on its vaccine news.
- 07/15/2020
|
Nasdaq Rises on Moderna Coronavirus Vaccine Hopes -- at Inovio's Expense
- The stock market moved higher Wednesday morning on optimism about a potential solution to the COVID-19 pandemic.
- 07/15/2020
|
Stocks making the biggest moves after hours: Sirius XM, Moderna, Lyft and more
- See which stocks are posting big moves after the bell.
- 07/14/2020
|
4 Top Stock Trades for Wednesday: JPM, DAL, FAST, INO
- Fastenal, Delta Air Lines, Inovio and JPMorgan were our top stock trades for Wednesday. That said, let's look at the charts moving forward.
- 07/14/2020
|
How the U.S. Constitution Is Helping Inovio Pharmaceuticals
- INO stock has transformed this year from unknown to a Wall Street darling. But with a worsening pandemic, the long-term case for Inovio has become even more credible.
- 07/14/2020
|
Here's Why Inovio Is The Front-Runner In Developing a Coronavirus Vaccine
- Vaccine development is not an all-or-nothing endeavor. INO-4800 can rake in hundreds of millions in revenue if approved, even if only partially successful.
- 07/14/2020
|
Here's Why Inovio Is The Front-Runner In Developing a Coronavirus Vaccine
- Vaccine development is not an all-or-nothing endeavor. INO-4800 can rake in hundreds of millions in revenue if approved, even if only partially successful.
- 07/14/2020
|
Vaccine Makers BioNTech, Moderna, And Novavax Set To Run Higher
- Stocks Analysis by Harry Boxer covering: KB Home, Vaxart Inc, Novavax Inc, Altimmune Inc. Read Harry Boxer's latest article on Investing.com
- 07/14/2020
|
SPDR Biotech ETF: Well-Diversified But Volatile And Overbought
- Investor interest in the biotech sector has remained elevated for most of 2020 and it does not look like this will ebb away soon.
- 07/13/2020
|
Is It Finally Time to Buy INO Stock?
- The world wants a Covid-19 vaccine, but for investors trying to improve the health of their portfolio, the only way to immunize properly in upstart Inovio is with this options strategy
The post Is It Finally Time to Buy INO Stock? appeared first on InvestorPlace.
- 07/13/2020
|
High-Grade Glioma Market Insights, Epidemiology and Forecast to 2030 - ResearchAndMarkets.com
|
Better Coronavirus Stock: Moderna or Inovio Pharmaceuticals?
- Optimistic investors are bidding up shares of both companies, but which one is the better stock pick?
- 07/12/2020
|
Could Buying Inovio Pharmaceuticals Stock Make You Rich?
- Over the five-year period leading up to 2020, Inovio Pharmaceuticals (NASDAQ: INO) delivered a positive return in just one year: In 2016, Inovio gained a little over 3%. The company has emerged as one of a handful of small drugmakers with promising COVID-19 vaccine candidates. Could buying Inovio stock now make you rich over the next several years?
- 07/12/2020
|
Better Coronavirus Stock: Moderna or Inovio Pharmaceuticals?
- Optimistic investors are bidding up shares of both companies, but which one is the better stock pick?
- 07/12/2020
|
Could Buying Inovio Pharmaceuticals Stock Make You Rich?
- The biotech stock has been a winner so far this year. But can Inovio's momentum continue?
- 07/12/2020
|
Coronavirus Vaccine Race: Moderna or Inovio?
- Multiple drugmakers are scrambling to develop COVID-19 vaccine candidates. In terms of clinical progress, Moderna (NASDAQ: MRNA) appears to be neck-and-neck for the lead with a partnership between AstraZeneca and the University of Oxford. The U.S. biotech hopes to begin a pivotal late-stage study of its COVID-19 vaccine candidate mRNA-1273 later this month.
- 07/11/2020
|
Coronavirus Vaccine Race: Moderna or Inovio?
- This story has a long way to go before being over.
- 07/11/2020
|
INO Stock Could Receive Operation Warp Speed Funding Soon
- Will Inovio (NASDAQ:INO) and INO stock explode, or is its run over? Creating vaccines requires massive resources. Thus, questions regarding the ability of smaller biotech companies to compete with their better-heeled and more experienced adversaries have persisted. Yet, the potential return on smaller biotech companies was and perhaps remains too tempting.Source: Ascannio / Shutterstock.com Reports that government scientists are having trouble running trials with Moderna (NASDAQ:MRNA) don't bode well for smaller biotech companies pursuing a vaccine. That much larger drug makers like Johnson & Johnson (NYSE:JNJ) have not received such complaints is telling. This points to the sophistication and advanced nature of the large drug makers' Covid-19 programs. Perhaps they are simply better versed in cooperating with the government. Nevertheless, investors should recognize the risk these smaller biotech stocks represent. Inovio may yet receive government funding and explode.InvestorPlace - Stock Market News, Stock Advice & Trading Tips A Reversal of Fortune at Inovio?Barron's reports a reversal of analyst sentiment regarding Inovio within the past month. One month ago the tally was five "buys," three "holds", and no "sells." Consensus was that the stock was overweight at that time. However, the current tally is two "buys," five "holds," and one "sell" with the consensus being to hold it. * The 7 Best Stocks to Invest in Right Now Investors should bear this change of sentiment in mind given recent news concerning Novavax (NASDAQ:NVAX) and Regeneron (NASDAQ:REGN). The federal government signed a $450 million contract with Regeneron to purchase as many as 1.3 million does of its antibody cocktail. Novavax announced that it received $1.6 billion to test its Covid-19 vaccine. Novavax does not have any commercially marketed products and yet it is receiving $1.6 billion in funding. Markets should interpret this as one of two things: either the government is hedging a massive bet, or it knows more about Novavax's vaccine than has been released. Given that Novavax shares popped 29% following the funding news, markets are betting on the latter. Inovio Seeking Government CooperationInovio's ability to leverage government relationships in the fight against the pandemic is crucial. It seeks to do what Novavax and Regeron have recently achieved. Former U.S. military vaccine and pandemic expert Dr. Mammen Mammen joined Inovio on June 25 to lead clinical development of the vaccine. Two days prior, Inovo received $71 million in funding to scale up manufacturing of its vaccine delivery device. Inovio's CELLECTRA 3PSP proprietary delivery device delivers INO-4800 directly into the skin. Investors are keenly scrutinizing these developments and their potential.Markets also want to know when peer review news will be released relating to INO-4800. This will be very important on the heels of the news released on June 30. Inovio's June 30 press release regarding phase 1 data for their INO-4800 vaccine didn't spike the price. Market reactions indicated some skepticism regarding Inovio's claims about INO-4800. Thus, investors will await peer review for the drug, which will likely serve to confirm or discredit the company-issued June 30 statement. Inovio also stated that it will begin a 2-stage trial in Korea. Inovio announced it added Gene Kim to its management team. He has a long history of leading Korean biotechs and previously helped list an IPO. INO Shares Might Rise to Warp SpeedThe federal government's largest expenditure in Operation Warp Speed thus far has been its bet on Novavax. The government's $1.6 billion bet is a clear indication that unproven biotech companies are a pillar of its Covid-19 strategy. Signs certainly point to a possible Operation Warp Speed funding announcement of Inovio in the coming weeks. Despite the market's tepid reception of Inovio's June news, there are signs of something big coming. The company is scrambling and aligning a coherent strategy in this volatile environment. Investors can also assume that a government funding deal is being discussed. Is INO Stock a Buy?INO stock is absolutely a hold and given all of the signs, one to consider as a Covid-19 play. Inovio has huge upside. The more I read about this stock the more I feel like investors are going to only regret not buying it. However, this is all speculation. Inovio could certainly strike out in regards to INO-4800. The company, however, has many other products in its pipeline and I can't help but feel like it's headed somewhere positive. As of writing, Alex Sirois does not own any of the aforementioned stocks. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post INO Stock Could Receive Operation Warp Speed Funding Soon appeared first on InvestorPlace.
- 07/10/2020
|
3 Reasons to Invest in, Not Trade iBio
- Stuck in a "soft" quarantine, I turned to what most people did during the hard quarantine - watch the film Contagion. It's been quite a while since I last saw the terrifying depiction of a devastating pandemic. After giving it another run through, I'm struck at how ominously accurate the movie is regarding the novel coronavirus. And this brings me to iBio (NYSEAMERICAN:IBIO) and specifically, IBIO stock.Source: Shutterstock Over the last few months that I covered this biotechnology firm, I described its equity as a speculative opportunity to advantage with "dumb" money. In other words, as a pure gamble, you could do a lot worse. Should the organization live up to its claim of mass-production of a coronavirus vaccine, IBIO stock could veritably skyrocket.But as shares have steadily ticked higher since early April and as demand for a vaccine consistently rises, I'm willing to sharpen my prognostication for iBio. Rather than it being a dumb money move, it's a rational one.InvestorPlace - Stock Market News, Stock Advice & Trading TipsDon't get me wrong - IBIO stock is still ultra-risky. However, what has given me more confidence in the underlying company is that a return to normalcy may be impossible without a biological solution to this crisis.In carefully watching Contagion, I realized what made this narrative so compelling from a filmmaking perspective is plot organization. Starting with the initial strike, the protagonists work through the fictional MEV-1 virus' second wave, which then culminates in a vaccine and its unwieldy distribution. * The 7 Best Stocks to Invest in Right Now Each segment in the film features its own conflict. What intrigued me about Contagion's final act was that the mere production of a vaccine wasn't enough. This brings me to my first of three bullish factors for iBio. Scale Is the Distinguisher for IBIO StockAs the New York Times spelled out a few months ago, several entities are developing a novel coronavirus vaccine. Contrary to some people's opinions, this development process is long, arduous and expensive. It's not as easy as injecting disinfectants.Therefore, you're looking at a two-front battle. First, a pharmaceutical company must forward a truly viable and effective vaccine. Second, it's got to bring that vaccine to scale so that the entire nation can benefit. Both challenges will be difficult to overcome.But as I pointed out in early June, scale is what distinguishes IBIO stock from the competition. I wrote:The driving force behind the company is a proprietary technology called the FastPharming Manufacturing System. Using a relative to the tobacco plant as a "bioreactor," iBio can theoretically take a vaccine and scale it up to necessary commercial volume. According to iBio co-chairman and CEO Tom Isett, the firm can "make about 500 million doses of high-quality product annually."Granted, the company must live up to its claims. Otherwise, it can go downhill quickly for IBIO stock. Nevertheless, if it can achieve this scale, the U.S. government's ambitious target to get a vaccine within a 12- to 18-month window is much more credible. Multiple Paths to SuccessAnother previously not well known pharmaceutical company in the coronavirus vaccine race is Inovio Pharmaceuticals (NASDAQ:INO). Despite question marks over its candidate's viability, INO shares are still performing outstandingly. In part, this may be because there are multiple paths to success.According to Dr. James Samuel, a regents' professor and the head of the Department of Microbial Pathogenesis and Immunology at the Texas A&M; University College of Medicine, initial coronavirus vaccines may be helpful for healthy individuals. However, Dr. Samuel cautioned that other vaccines may need to be developed for medically vulnerable individuals.As Dr. Samuel put it, "The challenge is a lot more complicated than a single vaccine… The scale of the problem alone is unprecedented. This will not be a horse race with a single winner."Therefore, just because a company beats everyone else to an effective vaccine doesn't spell disaster for others. First, scaling up that vaccine is a challenge, but one that would better suit iBio. Second, multiple vaccines may be necessary to fully address the Covid-19 pandemic.So, IBIO stock may have a safety margin that some investors may not be aware of. Economic Demand Is SurgingWhoever forwards genuine solutions, investors of that organization will find themselves loving life (assuming they don't get Covid-19 and die). But the financial implications of a vaccine don't just end on Wall Street. Indeed, the domestic and perhaps the international economy is dependent on it.For the most part, Americans have graciously adopted previously foreign practices, such as wearing masks and practicing social distancing. But skyrocketing new daily coronavirus cases, along with an uptick in Covid-19-related deaths have cast a shadow on these measures' efficacy.If only from the power of perception, the U.S. desperately needs a vaccine. It's much easier to convince businesses to reopen and people to spend if we have a substantive, meaningful solution.This also means that there's extra leeway in terms of the vaccine development process. Stated differently, a less-than-desirable result may not spell immediate red ink for pharmaceutical players. And that adds another measure of confidence toward IBIO stock.A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post 3 Reasons to Invest in, Not Trade iBio appeared first on InvestorPlace.
- 07/10/2020
|
Inovio Subcontractor Hits Back With Lawsuit Against Coronavirus Vaccine Developer
- Inovio Pharmaceuticals Inc (NASDAQ: INO) could be embroiled in a prolonged legal battle with its Blue Bell, Pennsylvania-headquartered subcontractor VGXI, Inc, after the subcontractor sued the pharma company. The Inovio Lawsuit: VGXI filed a lawsuit this week in the Montgomery County Court of Common Pleas, with the plaintiff accusing Inovio of breach of contract, unfair competition, misappropriation of trade secrets and unjust enrichment, the Philadelphia Business Journal reported.Inovio initiated legal proceedings against VGXI, a subsidiary of South Korea's GeneOne Life Sciences, in early June, accusing it of not transferring technical know-how to manufacture doses of INO-4800, Inovio's DNA vaccine candidate against SARS-CoV-2.Inovio's contention was that VGXI did not possess the wherewithal to scale up manufacturing, which is essential for getting regulatory clearance.In late June, the Montgomery County Court denied Inovio's request for an injunction against VGXI."Inovio got greedy. It saw the opportunity to reap vast riches and keep its stock price soaring if it could win the race to a COVID-19 vaccine, but Inovio did not want to pay VGXI for the manufacturing," VGXI reportedly said in the lawsuit.Inovio chose to unfairly take possession of VGXI's proprietary technology and manufacturing processes and pass on to as many as 10 other manufacturers around the world, including in China and India, the lawsuit alleges. What's Next For Inovio: The lawsuit from VGXI will not impact Inovio's coronavirus vaccine development, an Inovio spokesman told Benzinga in an email Friday. "If we have an effective vaccine, manufacturing will not be an issue," he said, adding that the Phase 2/3 trail for INO-4800 is on track to begin this summer.Inovio reported June 30 with interim results from a Phase 1 study of INO-4800, which showed that 94% of Phase 1 trial participants demonstrated immune responses at week six after two doses of INO-4800.The company also announced it has been selected to take part in a non-human primate challenge study under the federal government's Operation Warp Speed..Inovio shares were down 0.67% at $23.12 at last check.Related Links:Revisiting Coronavirus Vaccine Timelines: Moderna Denies Delay, Pfizer Advances Project Lightspeed And More Moderna Analyst Says Biotech Has 'First-To-Market' Potential For Coronavirus Vaccine See more from Benzinga * The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus * Inovio Plunges On Interim Phase 1 Coronavirus Data; DNA Vaccine Shows 94% Response Rate(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/10/2020
|
INO Stock Could Receive Operation Warp Speed Funding Soon
- Is Inovo's run over? There's actually a string of developments that could make INO stock explode following its meteoric rise.
- 07/10/2020
|
Inovio Subcontractor Hits Back With Lawsuit Against Coronavirus Vaccine Developer
- Inovio Pharmaceuticals Inc (NASDAQ: INO) could be embroiled in a prolonged legal battle with its Blue Bell, Pennsylvania-headquartered subcontractor VGXI, Inc, after the subcontractor sued the pharma company.
- 07/10/2020
|
9 Stocks to Buy in July as the Coronavirus Worsens
- With the pandemic rearing its ugly head again, these nine companies should give you significant growth potential.
- 07/09/2020
|
9 Stocks to Buy for a Wild Ride in July
- With rising coronavirus hospitalizations dominating headlines, investors will shift back toward a pandemic mentality. Here are nine stocks to buy to capitalize on this trend.
- 07/09/2020
|
In the Race to a Coronavirus Vaccine, Buy Moderna Stock or Inovio Stock?
- Shares of potential COVID-19 developers have surged with each bit of news. But one offers better prospects for investors.
- 07/09/2020
|
Without First Mover Advantage, Things Don’t Look Great for Inovio Stock
- Given Inovio's challenges and the very high valuation of INO stock, I recommend selling the shares.
The post Without First Mover Advantage, Things Don’t Look Great for Inovio Stock appeared first on InvestorPlace.
- 07/09/2020
|
Inovio’s Dramatic 30% Drop Will Be Short-Lived
- Fundamentally, the positive clinical data suggests that INO stock is on the right path to generating strong revenues as early as next year.
The post Inovio’s Dramatic 30% Drop Will Be Short-Lived appeared first on InvestorPlace.
- 07/09/2020
|
